{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# evaluation\n",
    "ragas ref:\n",
    "\n",
    "\n",
    "https://docs.ragas.io/en/stable/index.html"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "import sys\n",
    "import logging\n",
    "\n",
    "from llama_index.core import StorageContext, load_index_from_storage\n",
    "\n",
    "from llama_index.core.retrievers import VectorIndexRetriever\n",
    "\n",
    "from llama_index.core import Settings\n",
    "\n",
    "from llama_index.embeddings.openai import OpenAIEmbedding\n",
    "from llama_index.llms.openai import OpenAI\n",
    "\n",
    "from llama_index.core.data_structs import Node\n",
    "from llama_index.core.schema import NodeWithScore\n",
    "from llama_index.core import get_response_synthesizer\n",
    "\n",
    "\n",
    "import openai\n",
    "\n",
    "import nest_asyncio\n",
    "nest_asyncio.apply()\n",
    "\n",
    "import logging\n",
    "import sys\n",
    "\n",
    "logging.basicConfig(stream=sys.stdout, level=logging.INFO)\n",
    "logging.getLogger().addHandler(logging.StreamHandler(stream=sys.stdout))\n",
    "\n",
    "from llama_index.llms.openai import OpenAI\n",
    "from IPython.display import Markdown, display\n",
    "\n",
    "from llama_index.core.retrievers import VectorIndexRetriever\n",
    "from llama_index.core import QueryBundle\n",
    "from llama_index.postprocessor.rankgpt_rerank import RankGPTRerank\n",
    "\n",
    "import pandas as pd\n",
    "from IPython.display import display, HTML\n",
    "\n",
    "\n",
    "load_dotenv()  # Load environment variables from .env file\n",
    "openai.api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "\n",
    "OPENAI_API_KEY = openai.api_key\n",
    "\n",
    "Settings.llm = OpenAI(temperature=0, model=\"gpt-3.5-turbo\")\n",
    "Settings.embed_model = OpenAIEmbedding(model=\"text-embedding-3-large\")\n",
    "\n",
    "\n",
    "logging.basicConfig(stream=sys.stdout, level=logging.INFO)\n",
    "logging.getLogger().addHandler(logging.StreamHandler(stream=sys.stdout))\n",
    "\n",
    "\n",
    "%load_ext autoreload\n",
    "%autoreload 2\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "INFO:llama_index.core.indices.loading:Loading all indices.\n",
      "Loading all indices.\n",
      "Loading all indices.\n",
      "INFO:httpx:HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"\n",
      "INFO:httpx:HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"\n",
      "After Reranking, new rank list for nodes: [0, 6, 3, 1, 2, 7, 8, 25, 13, 23, 27, 9, 24, 14, 26, 15, 16, 20, 18, 19, 21, 28, 17, 10, 4, 5, 11, 12, 29, 22]INFO:httpx:HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "Response(response='Potential consequences of Keytruda include immune-related adverse effects such as colitis, hepatitis, pneumonitis, and exacerbation of pre-existing autoimmune diseases. It is important for patients to monitor for symptoms like cough, shortness of breath, chest pain, and changes in vision while on Keytruda treatment to ensure optimal care and safety.', source_nodes=[NodeWithScore(node=TextNode(id_='1c86f3e8-53f4-417a-9c1b-81fb42255e97', embedding=None, metadata={'document_title': 'Keytruda and Immune-Related Adverse Effects: A Comprehensive Overview'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='49de588d-beb9-4e7e-84dc-06ffb2e63a2d', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='c73be1b4e2cb5e6157fd80000f0fe59f6ca8631fa4924c5ed0be7dd3180c3218')}, text='Can Keytruda cause immune-related adverse effects? Yes, Keytruda can cause immune-related adverse effects such as colitis, hepatitis, and pneumonitis.', mimetype='text/plain', start_char_idx=0, end_char_idx=150, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6946757102739912), NodeWithScore(node=TextNode(id_='6769e1e6-7182-41b8-9f5a-498971f6a7ab', embedding=None, metadata={'document_title': \"Keytruda's Dual Impact on Immune System Function in Non-Small Cell Lung Cancer Patients: A Comprehensive Review\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='47b3ef42-c71e-4a91-8814-d07937aae69e', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='e12b51245aa4983a9f49193844a23111cb167b4b00c8d446eb4db98f97a74af8')}, text=\"How does Keytruda affect immune system function in NSCLC patients? Keytruda enhances the immune system's ability to detect and destroy cancer cells but can also lead to immune-related adverse effects that need to be managed.\", mimetype='text/plain', start_char_idx=0, end_char_idx=224, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6307428537125984), NodeWithScore(node=TextNode(id_='82c7d105-9423-4af9-b9e9-e48a1b5c87f8', embedding=None, metadata={'document_title': 'Keytruda Use in NSCLC Patients with Autoimmune Diseases: Caution Advised'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='d2d6ade0-d86c-441f-9bae-6d22c5400925', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='d6006a9d9525d8f9c40c21e1768057a9ab8ebe753bb9f9b1fbe831a9c6b62979')}, text='Can Keytruda be used in NSCLC patients with autoimmune diseases? Keytruda should be used with caution in patients with pre-existing autoimmune diseases due to the risk of exacerbating the condition.', mimetype='text/plain', start_char_idx=0, end_char_idx=198, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6329186177011589), NodeWithScore(node=TextNode(id_='42490fd1-3472-46b2-a045-3c674b8c4d45', embedding=None, metadata={'document_title': 'Monitoring Keytruda Side Effects in NSCLC Patients: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='e6afb036-e8de-4798-ac85-b11e7126d096', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='c836b84f73a24eb1651123703374f4762bd0bd27f62b0153ea405e07244ce7ef')}, text='Are there specific side effects of Keytruda that NSCLC patients should monitor? NSCLC patients should monitor for cough, shortness of breath, and chest pain, as these could indicate immune-related pneumonitis.', mimetype='text/plain', start_char_idx=0, end_char_idx=209, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6553666410743483), NodeWithScore(node=TextNode(id_='08a41277-3e68-438d-a1ef-0e5cee2fee19', embedding=None, metadata={'document_title': 'Keytruda Treatment: Reporting Symptoms Immediately for Optimal Care and Safety'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='036d6935-3d22-4899-8e00-187bc1f19455', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='ece4cc1d01c5ca9149d1021a1bef61325dc0d0ddc383e236acdc57517e0e59cf')}, text='What should patients report immediately while on Keytruda treatment? Patients should report any new or worsening symptoms such as cough, chest pain, or changes in vision immediately.', mimetype='text/plain', start_char_idx=0, end_char_idx=182, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6432255145810415)], metadata={'1c86f3e8-53f4-417a-9c1b-81fb42255e97': {'document_title': 'Keytruda and Immune-Related Adverse Effects: A Comprehensive Overview'}, '6769e1e6-7182-41b8-9f5a-498971f6a7ab': {'document_title': \"Keytruda's Dual Impact on Immune System Function in Non-Small Cell Lung Cancer Patients: A Comprehensive Review\"}, '82c7d105-9423-4af9-b9e9-e48a1b5c87f8': {'document_title': 'Keytruda Use in NSCLC Patients with Autoimmune Diseases: Caution Advised'}, '42490fd1-3472-46b2-a045-3c674b8c4d45': {'document_title': 'Monitoring Keytruda Side Effects in NSCLC Patients: A Comprehensive Guide'}, '08a41277-3e68-438d-a1ef-0e5cee2fee19': {'document_title': 'Keytruda Treatment: Reporting Symptoms Immediately for Optimal Care and Safety'}})"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Rebuild the storage context\n",
    "storage_context = StorageContext.from_defaults(persist_dir=\"./persist\")\n",
    "\n",
    "# Load the index from storage\n",
    "index = load_index_from_storage(storage_context)\n",
    "\n",
    "\n",
    "\n",
    "def get_retrieved_nodes(\n",
    "    query_str, vector_top_k=10, reranker_top_n=3, with_reranker=False\n",
    "):\n",
    "    query_bundle = QueryBundle(query_str)\n",
    "    # configure retriever\n",
    "    retriever = VectorIndexRetriever(\n",
    "        index=index,\n",
    "        similarity_top_k=vector_top_k,\n",
    "    )\n",
    "    retrieved_nodes = retriever.retrieve(query_bundle)\n",
    "\n",
    "    if with_reranker:\n",
    "        # configure reranker\n",
    "        reranker = RankGPTRerank(\n",
    "            llm=OpenAI(\n",
    "               model=\"gpt-3.5-turbo\",\n",
    "               temperature=0.0,\n",
    "               api_key=OPENAI_API_KEY,\n",
    "            ),\n",
    "            top_n=reranker_top_n,\n",
    "            verbose=True,\n",
    "        )\n",
    "        retrieved_nodes = reranker.postprocess_nodes(\n",
    "            retrieved_nodes, query_bundle\n",
    "        )\n",
    "\n",
    "    return retrieved_nodes\n",
    "\n",
    "\n",
    "\n",
    "query = \"What are potential CONSECUENCES of keytruda?\"\n",
    "retrieved_nodes = get_retrieved_nodes(\n",
    "    query,\n",
    "    vector_top_k=30,\n",
    "    reranker_top_n=5,\n",
    "    with_reranker=True,\n",
    ")\n",
    "\n",
    "response_synthesizer = get_response_synthesizer(response_mode=\"compact\")\n",
    "\n",
    "response = response_synthesizer.synthesize(\n",
    "    query, nodes=retrieved_nodes\n",
    ")\n",
    "\n",
    "response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "INFO:httpx:HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"\n",
      "INFO:httpx:HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "Response(response='Potential consequences of Keytruda include immune-related adverse effects such as colitis, hepatitis, and pneumonitis, as well as changes in blood pressure, interactions with steroids and immunosuppressants, and the need for close monitoring for specific symptoms like cough, chest pain, and changes in vision. Additionally, Keytruda may lead to exacerbation of pre-existing autoimmune diseases and require discontinuation in cases of significant disease progression or unacceptable toxicity.', source_nodes=[NodeWithScore(node=TextNode(id_='1c86f3e8-53f4-417a-9c1b-81fb42255e97', embedding=None, metadata={'document_title': 'Keytruda and Immune-Related Adverse Effects: A Comprehensive Overview'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='49de588d-beb9-4e7e-84dc-06ffb2e63a2d', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='c73be1b4e2cb5e6157fd80000f0fe59f6ca8631fa4924c5ed0be7dd3180c3218')}, text='Can Keytruda cause immune-related adverse effects? Yes, Keytruda can cause immune-related adverse effects such as colitis, hepatitis, and pneumonitis.', mimetype='text/plain', start_char_idx=0, end_char_idx=150, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.694663961618386), NodeWithScore(node=TextNode(id_='42490fd1-3472-46b2-a045-3c674b8c4d45', embedding=None, metadata={'document_title': 'Monitoring Keytruda Side Effects in NSCLC Patients: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='e6afb036-e8de-4798-ac85-b11e7126d096', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='c836b84f73a24eb1651123703374f4762bd0bd27f62b0153ea405e07244ce7ef')}, text='Are there specific side effects of Keytruda that NSCLC patients should monitor? NSCLC patients should monitor for cough, shortness of breath, and chest pain, as these could indicate immune-related pneumonitis.', mimetype='text/plain', start_char_idx=0, end_char_idx=209, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6553953614397532), NodeWithScore(node=TextNode(id_='08a41277-3e68-438d-a1ef-0e5cee2fee19', embedding=None, metadata={'document_title': 'Keytruda Treatment: Reporting Symptoms Immediately for Optimal Care and Safety'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='036d6935-3d22-4899-8e00-187bc1f19455', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='ece4cc1d01c5ca9149d1021a1bef61325dc0d0ddc383e236acdc57517e0e59cf')}, text='What should patients report immediately while on Keytruda treatment? Patients should report any new or worsening symptoms such as cough, chest pain, or changes in vision immediately.', mimetype='text/plain', start_char_idx=0, end_char_idx=182, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6432166211652168), NodeWithScore(node=TextNode(id_='82c7d105-9423-4af9-b9e9-e48a1b5c87f8', embedding=None, metadata={'document_title': 'Keytruda Use in NSCLC Patients with Autoimmune Diseases: Caution Advised'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='d2d6ade0-d86c-441f-9bae-6d22c5400925', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='d6006a9d9525d8f9c40c21e1768057a9ab8ebe753bb9f9b1fbe831a9c6b62979')}, text='Can Keytruda be used in NSCLC patients with autoimmune diseases? Keytruda should be used with caution in patients with pre-existing autoimmune diseases due to the risk of exacerbating the condition.', mimetype='text/plain', start_char_idx=0, end_char_idx=198, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6328933215727313), NodeWithScore(node=TextNode(id_='64096ccf-4e98-4416-86cb-b1d896231199', embedding=None, metadata={'document_title': 'Keytruda and Blood Pressure Changes: Understanding the Relationship and Implications'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='2033f1e0-dbd3-4838-b607-3a9a2d3f8844', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='4b18e3384a842ce815e6bdce35bf79b0fff938dc138b2aea40bc50b5703eb955')}, text='Can Keytruda cause changes in blood pressure? Yes, fluctuations in blood pressure can occur, and patients should monitor their blood pressure regularly.', mimetype='text/plain', start_char_idx=0, end_char_idx=152, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.631291770411566), NodeWithScore(node=TextNode(id_='6e3d4a37-d467-4472-8c26-d04a1f5bf215', embedding=None, metadata={'document_title': 'Common Side Effects of Keytruda: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='a800f0aa-054f-4ed7-8ab4-7931c0b9b874', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='e5a39cfff146f563f89b2818c0eff8c96284c5f2ef84443f0245b56e5852daf4')}, text='What are the common side effects of Keytruda? Common side effects include fatigue, nausea, and skin rash.', mimetype='text/plain', start_char_idx=0, end_char_idx=105, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6310254874117461), NodeWithScore(node=TextNode(id_='6769e1e6-7182-41b8-9f5a-498971f6a7ab', embedding=None, metadata={'document_title': \"Keytruda's Dual Impact on Immune System Function in Non-Small Cell Lung Cancer Patients: A Comprehensive Review\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='47b3ef42-c71e-4a91-8814-d07937aae69e', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='e12b51245aa4983a9f49193844a23111cb167b4b00c8d446eb4db98f97a74af8')}, text=\"How does Keytruda affect immune system function in NSCLC patients? Keytruda enhances the immune system's ability to detect and destroy cancer cells but can also lead to immune-related adverse effects that need to be managed.\", mimetype='text/plain', start_char_idx=0, end_char_idx=224, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6307792765264351), NodeWithScore(node=TextNode(id_='eea58cb1-6d6b-48bf-8477-760409f4047d', embedding=None, metadata={'document_title': 'Interactions of Keytruda with Steroids and Immunosuppressants: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='987f65cf-e7fa-426b-9dee-bcb319fbd0eb', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='1647b8ddf165cd4ee7bacab5592a24b4855623ccc473132a13c588692b32adef')}, text='Are there any known interactions between Keytruda and other medications? Yes, Keytruda can interact with steroids and certain immunosuppressants, potentially affecting its efficacy and safety.', mimetype='text/plain', start_char_idx=0, end_char_idx=192, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6122554203332318), NodeWithScore(node=TextNode(id_='51cbfd01-e017-42de-a362-35deae677033', embedding=None, metadata={'document_title': 'Monitoring Protocols for NSCLC Patients on Keytruda: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='998066fe-4f64-4047-81ec-e5f27c9c8b71', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='8ece3cf9c35dc00341732316c58b9e50d78e2c1e752cb31e55dc92bfdfd0598d')}, text='Are there any specific monitoring protocols for NSCLC patients on Keytruda as suggested by KEYNOTE-006 outcomes? Regular monitoring of liver function, lung function, and immune markers is recommended to manage potential side effects effectively.', mimetype='text/plain', start_char_idx=0, end_char_idx=245, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6026794125699548), NodeWithScore(node=TextNode(id_='7dbe67da-6f12-4c72-b628-73539e76d315', embedding=None, metadata={'document_title': 'Treatment of NSCLC Patients with Brain Metastases Using Keytruda: Importance of Close Monitoring for Neurological Symptoms'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='48e47199-0c64-40eb-a474-2ef74addbaec', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='473c19f8e08f4dad458c9324b04d890d68b306b29eedf95c765f6305256b0652')}, text='Can NSCLC patients with brain metastases be treated with Keytruda? Keytruda can be used in NSCLC patients with brain metastases, especially when systemic disease control is needed, but close monitoring for neurological symptoms is essential.', mimetype='text/plain', start_char_idx=0, end_char_idx=241, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6009954677797894), NodeWithScore(node=TextNode(id_='5f426814-a97f-444e-9e11-ae49bfd754d0', embedding=None, metadata={'document_title': 'Side Effects in KEYNOTE-006 Trial: A Comprehensive Analysis'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='e679712a-9d64-446e-8392-a8119382e131', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='52217f9f5838b33448bea23a48004bd2620c4e6e5da0e6ef582fb74435b671ff')}, text='What were the side effects noted in the KEYNOTE-006 trial? Common side effects included fatigue, itching, and diarrhea.', mimetype='text/plain', start_char_idx=0, end_char_idx=119, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.594317177316895), NodeWithScore(node=TextNode(id_='9410a4fa-12e0-49d0-9a10-27cbad12b258', embedding=None, metadata={'document_title': 'Keytruda and Fatigue in NSCLC Patients: Understanding the Impact of Immunotherapy on Energy Levels'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='8a33e7be-bb66-46e6-aee0-81fe1bd2011b', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='b1e1969e11c284e71c9f2530c3e448ec900cd1a9391f7507ede56fd3401224f1')}, text='Can Keytruda cause fatigue in NSCLC patients? No detailed information aviable on the given topic.', mimetype='text/plain', start_char_idx=0, end_char_idx=97, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5868933925778926), NodeWithScore(node=TextNode(id_='7e5d5dcc-7c95-4fbe-ba74-037aa6e41ca3', embedding=None, metadata={'document_title': 'Safety of Keytruda in Pregnancy: A Comprehensive Review'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='e2873838-e865-4cad-9d6f-5cdf0f2db7d2', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='583eb4caa1acdd76a69a5a2568c582a8d1b24bf01b5232055a763bb6cd4b00a1')}, text='Is Keytruda safe for pregnant women? Keytruda is not recommended for use during pregnancy due to potential risks to the fetus.', mimetype='text/plain', start_char_idx=0, end_char_idx=126, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5866833520428139), NodeWithScore(node=TextNode(id_='c327f89d-31c2-4eef-909c-ad11bf2ce74a', embedding=None, metadata={'document_title': 'Criteria for Discontinuing Keytruda in Non-Small Cell Lung Cancer Patients: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='2f328ea4-c5a8-4320-b88f-2ca1cbe2911b', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='32af240e9f1d3da212ca6def5a4e93468a5c04d3f38f989501f5131ec2761d9e')}, text='What are the criteria for discontinuing Keytruda in NSCLC patients? Keytruda may be discontinued if there is significant disease progression, unacceptable toxicity, or upon patient decision in consultation with their healthcare provider.', mimetype='text/plain', start_char_idx=0, end_char_idx=237, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5731272181379368), NodeWithScore(node=TextNode(id_='cb5773a5-e9fa-43cd-a852-25da66db70e2', embedding=None, metadata={'document_title': 'Comprehensive Patient Education on Keytruda: Understanding the Benefits, Risks, and Follow-Up Care'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='03af9a2f-372c-4bc6-8b4c-86f2e38f5588', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='686b693be1f48bc18db21fcd4a928c3180cd73f4745d4dfd26a532a14c46aa5a')}, text='How do healthcare providers educate patients about the benefits and risks of Keytruda? Healthcare providers offer educational materials, detailed consultations, and regular follow-up to discuss treatment progress and side effects.', mimetype='text/plain', start_char_idx=0, end_char_idx=230, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5697375183861451), NodeWithScore(node=TextNode(id_='a3e4ba87-85d6-4b7f-b38e-261a733cdfb8', embedding=None, metadata={'document_title': \"Keytruda's Impact on Metastatic NSCLC: Progression Reduction and Survival Improvement in Patients\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='172b6ea5-2346-4c47-9f4e-c6cd77f83ba4', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='a09dfd6a82cdfee88b2c5772f18613aa634b9ec8cbb9de170d6db265970189f4')}, text='What was the impact of Keytruda on metastatic NSCLC in the KEYNOTE-051 trial? Keytruda significantly reduced the progression of metastatic disease and improved survival rates in metastatic NSCLC patients.', mimetype='text/plain', start_char_idx=0, end_char_idx=204, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5690369437389019), NodeWithScore(node=TextNode(id_='0cd2c9ce-7345-42dd-bebe-648a3d83d682', embedding=None, metadata={'document_title': 'Positive Response to Keytruda in NSCLC: Tumor Size Reduction, Respiratory Symptom Improvement, and Increased Well-Being in Patients with Non-Small Cell Lung Cancer'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='c5455699-72e7-4ac1-9219-e52b248fd229', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='88c382ad9222a2052c23403c6568abb17f7fa4f31c9e97c68ca8c67f56e5753f')}, text='What are the signs of a positive response to Keytruda in NSCLC? Signs include a decrease in tumor size on imaging, improvement in respiratory symptoms, and increased overall physical activity and well-being.', mimetype='text/plain', start_char_idx=0, end_char_idx=207, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5593613223061357), NodeWithScore(node=TextNode(id_='5f013f4e-d7c3-4183-8bb3-7a47a4fa5247', embedding=None, metadata={'document_title': '\"Keytruda: Rapid Effects in Cancer Treatment - A Comprehensive Overview\"'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='5e1cc82f-8dfd-4ed1-a328-f65bd5fc0d35', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='e603b5a6c3801d39d0f5cf61121c09f7b5b31749c5814f1b476627cdd8084a6e')}, text='How long does it take to see the effects of Keytruda in treating cancer? Some patients may see effects as early as 2 to 3 months into the treatment.', mimetype='text/plain', start_char_idx=0, end_char_idx=148, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5542067780550881), NodeWithScore(node=TextNode(id_='85550009-23c9-4640-850f-4898397a3f59', embedding=None, metadata={'document_title': 'The Impact of Keytruda on Survival Rates in Non-Small Cell Lung Cancer Patients with PD-L1 Expression'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='4def5d5e-7e3a-4924-aa4d-1f1471c79b90', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='c94df6025cefcf1493fb5461c551250192d9938b7a0b3fae81bbd7dd0dfa9dd6')}, text='How effective is Keytruda in treating non-small cell lung cancer? Keytruda has shown to improve survival rates significantly in non-small cell lung cancer patients with PD-L1 expression.', mimetype='text/plain', start_char_idx=0, end_char_idx=186, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5468067659649933), NodeWithScore(node=TextNode(id_='8c1e8f5a-13b3-4097-92ed-918c596df1ac', embedding=None, metadata={'document_title': \"Keytruda's Effectiveness in Various Cancer Types: A Comprehensive Review\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='3eeccdc7-8fe1-4c2f-b3ce-c805269deea5', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='211fd7fe5d712aa71ad65225538e8c34784a890315e2295a6f2d3c0ec5b2a05c')}, text='Does Keytruda work for all types of cancer? Keytruda is most effective in cancers that express PD-L1 and in a genetic background favorable to immune therapy.', mimetype='text/plain', start_char_idx=0, end_char_idx=157, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5468042482256105), NodeWithScore(node=TextNode(id_='c3df4d91-a194-4217-95e1-ce3522c6560f', embedding=None, metadata={'document_title': \"Keytruda's Superiority in Improving Survival Rates for NSCLC Patients with High PD-L1 Expression: A Comprehensive Analysis\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='ec5f23e6-e468-4d61-a9bb-36dfecc2b72f', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='3b1dad66a83bd670df1e309367e273229a37f197a7c87c715f495efc3276e4e9')}, text='How does Keytruda improve survival rates in NSCLC patients compared to traditional treatments? Keytruda has been shown to improve the overall survival rates by reducing the risk of death by about 40% compared to traditional chemotherapy in patients with high PD-L1 expression.', mimetype='text/plain', start_char_idx=0, end_char_idx=276, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5431979148573903), NodeWithScore(node=TextNode(id_='ff00c4a3-45e0-425e-8ea7-5a08a272c9d1', embedding=None, metadata={'document_title': 'Keytruda Treatment Response Rate in Melanoma Patients: A Comprehensive Review'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='1076524e-02d4-4afd-b5c7-41e4890f7b11', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='eeb978316d5f07d2b6c828a5ab96c5fb04c5a0dde90346ba8100320f7035a8ca')}, text='What is the response rate of melanoma patients treated with Keytruda? Approximately 40% of melanoma patients respond positively to Keytruda treatment.', mimetype='text/plain', start_char_idx=0, end_char_idx=150, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5427039361472236), NodeWithScore(node=TextNode(id_='b139d3ef-12b2-4f0f-9254-d72f61f599d9', embedding=None, metadata={'document_title': \"Keytruda's Five-Year Survival Rate for Lung Cancer Patients: A Comprehensive Review\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='8a302781-7928-4a1e-bf15-e860c40adde6', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='cc5f7e805e3eb8dc3bac1c5bb409348154aa1b6ea31e5ed498c08c45fea6ed1b')}, text='What is the five-year survival rate for patients using Keytruda for lung cancer? No detailed information aviable on the given topic.', mimetype='text/plain', start_char_idx=0, end_char_idx=132, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5400697575185366), NodeWithScore(node=TextNode(id_='39aa151b-376f-4262-8d54-55600a323763', embedding=None, metadata={'document_title': 'Combination Therapies with Keytruda for Enhanced Cancer Treatment: A Comprehensive Overview'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='433dd35b-1d97-4c68-9594-545629b5b4f3', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='12a8d2b371d47dda014ac33af341be6d82415dd681b26dececc4838a7f330600')}, text='Can Keytruda be used in combination with other therapies? Yes, Keytruda can be used in combination with chemotherapy and other immunotherapies depending on the cancer type.', mimetype='text/plain', start_char_idx=0, end_char_idx=172, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5381536492337425), NodeWithScore(node=TextNode(id_='0111506d-006c-48b7-9ba2-7038fc2f4424', embedding=None, metadata={'document_title': 'Enhancing NSCLC Treatment with Keytruda Combination Therapy: A Comprehensive Review'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='58484f72-869e-4623-8e75-af551586f3e0', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='0d5b90b6f05e5f043dcfe0b79950ef0294571dfc808c9fc452ff3dbf368de11e')}, text='How does Keytruda work in combination with other therapies for NSCLC?  Keytruda works synergistically with chemotherapy and other immunotherapies to enhance the immune response against cancer cells, often leading to improved outcomes.', mimetype='text/plain', start_char_idx=0, end_char_idx=234, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.531148675573835), NodeWithScore(node=TextNode(id_='24cf31ff-55fe-47a1-8d05-c5c671cc75bd', embedding=None, metadata={'document_title': 'Treatment Options for Non-Responding NSCLC Patients: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='cdc394fe-4fb1-4a32-9ec6-ff83e6360acc', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='53c0b1967dd5ba99d4c7ead9a19b9ad2ecd3df6d6e4ad6ae32ddc7c7a73f4e4f')}, text='What are the options if an NSCLC patient does not respond to Keytruda? For non-responders, options may include switching to different immunotherapy drugs, combination therapies with chemotherapy, or targeted therapies based on genetic mutations.', mimetype='text/plain', start_char_idx=0, end_char_idx=245, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5310518933210604), NodeWithScore(node=TextNode(id_='5e304353-3439-461b-91ab-639a11bf7dae', embedding=None, metadata={'document_title': 'Keytruda Support Community: Sharing Experiences and Advice'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='7ec77fae-086c-43bb-a92e-91c1d4d435e7', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='eb3f5ae6f374cc93ba105088a7e6f71e15ade3db30aaacc0daa77a017231d428')}, text='Is there a community support group for patients undergoing treatment with Keytruda? Yes, several online and local support groups are available for sharing experiences and advice.', mimetype='text/plain', start_char_idx=0, end_char_idx=178, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.528020098843247), NodeWithScore(node=TextNode(id_='aa0b8a1a-6bf8-45de-87a9-369873d76e93', embedding=None, metadata={'document_title': \"Guidelines for Keytruda in the Treatment of Hodgkin's Lymphoma\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='621e90d2-0989-4dd8-bd94-cbedad0d4aac', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='74ca0cad5d3066e93179bf0032fa6ddfd1525d1d506296b91f301f7b1c92b67d')}, text=\"What are the guidelines for Keytruda in treating Hodgkin's lymphoma? Keytruda is recommended for relapsed or refractory classical Hodgkin lymphoma after two or more lines of therapy.\", mimetype='text/plain', start_char_idx=0, end_char_idx=182, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5234026400016973), NodeWithScore(node=TextNode(id_='31dbb54c-b740-40f5-9f86-15b05aafecf9', embedding=None, metadata={'document_title': 'Keytruda Dosage Recommendations for Melanoma Treatment'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='642f3089-69ce-452c-afd7-ab2f6ad29f88', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='398aec4e73b60ec219102c812038d8f71b49e6f1289cdd58ee8d1f40b515e6de')}, text='What is the recommended dosage of Keytruda for melanoma? The recommended dosage is 200 mg every three weeks for adults.', mimetype='text/plain', start_char_idx=0, end_char_idx=119, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.523276235698616), NodeWithScore(node=TextNode(id_='0f9aa112-e9e2-48df-87db-23cbbba2b38f', embedding=None, metadata={'document_title': 'Keytruda Administration: Comprehensive Guide for Intravenous Infusion Over 30 Minutes'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='90836c65-0674-4663-867f-576e0068569a', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='1b49e5c862a94574d8068d5c00457f2698e05dd8c98cec8ee3c68720053a7ba9')}, text='How is Keytruda administered? Keytruda is administered as an intravenous infusion over 30 minutes.', mimetype='text/plain', start_char_idx=0, end_char_idx=98, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5216558196528691)], metadata={'1c86f3e8-53f4-417a-9c1b-81fb42255e97': {'document_title': 'Keytruda and Immune-Related Adverse Effects: A Comprehensive Overview'}, '42490fd1-3472-46b2-a045-3c674b8c4d45': {'document_title': 'Monitoring Keytruda Side Effects in NSCLC Patients: A Comprehensive Guide'}, '08a41277-3e68-438d-a1ef-0e5cee2fee19': {'document_title': 'Keytruda Treatment: Reporting Symptoms Immediately for Optimal Care and Safety'}, '82c7d105-9423-4af9-b9e9-e48a1b5c87f8': {'document_title': 'Keytruda Use in NSCLC Patients with Autoimmune Diseases: Caution Advised'}, '64096ccf-4e98-4416-86cb-b1d896231199': {'document_title': 'Keytruda and Blood Pressure Changes: Understanding the Relationship and Implications'}, '6e3d4a37-d467-4472-8c26-d04a1f5bf215': {'document_title': 'Common Side Effects of Keytruda: A Comprehensive Guide'}, '6769e1e6-7182-41b8-9f5a-498971f6a7ab': {'document_title': \"Keytruda's Dual Impact on Immune System Function in Non-Small Cell Lung Cancer Patients: A Comprehensive Review\"}, 'eea58cb1-6d6b-48bf-8477-760409f4047d': {'document_title': 'Interactions of Keytruda with Steroids and Immunosuppressants: A Comprehensive Guide'}, '51cbfd01-e017-42de-a362-35deae677033': {'document_title': 'Monitoring Protocols for NSCLC Patients on Keytruda: A Comprehensive Guide'}, '7dbe67da-6f12-4c72-b628-73539e76d315': {'document_title': 'Treatment of NSCLC Patients with Brain Metastases Using Keytruda: Importance of Close Monitoring for Neurological Symptoms'}, '5f426814-a97f-444e-9e11-ae49bfd754d0': {'document_title': 'Side Effects in KEYNOTE-006 Trial: A Comprehensive Analysis'}, '9410a4fa-12e0-49d0-9a10-27cbad12b258': {'document_title': 'Keytruda and Fatigue in NSCLC Patients: Understanding the Impact of Immunotherapy on Energy Levels'}, '7e5d5dcc-7c95-4fbe-ba74-037aa6e41ca3': {'document_title': 'Safety of Keytruda in Pregnancy: A Comprehensive Review'}, 'c327f89d-31c2-4eef-909c-ad11bf2ce74a': {'document_title': 'Criteria for Discontinuing Keytruda in Non-Small Cell Lung Cancer Patients: A Comprehensive Guide'}, 'cb5773a5-e9fa-43cd-a852-25da66db70e2': {'document_title': 'Comprehensive Patient Education on Keytruda: Understanding the Benefits, Risks, and Follow-Up Care'}, 'a3e4ba87-85d6-4b7f-b38e-261a733cdfb8': {'document_title': \"Keytruda's Impact on Metastatic NSCLC: Progression Reduction and Survival Improvement in Patients\"}, '0cd2c9ce-7345-42dd-bebe-648a3d83d682': {'document_title': 'Positive Response to Keytruda in NSCLC: Tumor Size Reduction, Respiratory Symptom Improvement, and Increased Well-Being in Patients with Non-Small Cell Lung Cancer'}, '5f013f4e-d7c3-4183-8bb3-7a47a4fa5247': {'document_title': '\"Keytruda: Rapid Effects in Cancer Treatment - A Comprehensive Overview\"'}, '85550009-23c9-4640-850f-4898397a3f59': {'document_title': 'The Impact of Keytruda on Survival Rates in Non-Small Cell Lung Cancer Patients with PD-L1 Expression'}, '8c1e8f5a-13b3-4097-92ed-918c596df1ac': {'document_title': \"Keytruda's Effectiveness in Various Cancer Types: A Comprehensive Review\"}, 'c3df4d91-a194-4217-95e1-ce3522c6560f': {'document_title': \"Keytruda's Superiority in Improving Survival Rates for NSCLC Patients with High PD-L1 Expression: A Comprehensive Analysis\"}, 'ff00c4a3-45e0-425e-8ea7-5a08a272c9d1': {'document_title': 'Keytruda Treatment Response Rate in Melanoma Patients: A Comprehensive Review'}, 'b139d3ef-12b2-4f0f-9254-d72f61f599d9': {'document_title': \"Keytruda's Five-Year Survival Rate for Lung Cancer Patients: A Comprehensive Review\"}, '39aa151b-376f-4262-8d54-55600a323763': {'document_title': 'Combination Therapies with Keytruda for Enhanced Cancer Treatment: A Comprehensive Overview'}, '0111506d-006c-48b7-9ba2-7038fc2f4424': {'document_title': 'Enhancing NSCLC Treatment with Keytruda Combination Therapy: A Comprehensive Review'}, '24cf31ff-55fe-47a1-8d05-c5c671cc75bd': {'document_title': 'Treatment Options for Non-Responding NSCLC Patients: A Comprehensive Guide'}, '5e304353-3439-461b-91ab-639a11bf7dae': {'document_title': 'Keytruda Support Community: Sharing Experiences and Advice'}, 'aa0b8a1a-6bf8-45de-87a9-369873d76e93': {'document_title': \"Guidelines for Keytruda in the Treatment of Hodgkin's Lymphoma\"}, '31dbb54c-b740-40f5-9f86-15b05aafecf9': {'document_title': 'Keytruda Dosage Recommendations for Melanoma Treatment'}, '0f9aa112-e9e2-48df-87db-23cbbba2b38f': {'document_title': 'Keytruda Administration: Comprehensive Guide for Intravenous Infusion Over 30 Minutes'}})"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from llama_index.core.query_engine import CustomQueryEngine\n",
    "from llama_index.core.retrievers import BaseRetriever\n",
    "from llama_index.core import get_response_synthesizer\n",
    "from llama_index.core.response_synthesizers import BaseSynthesizer\n",
    "\n",
    "class RAGQueryEngine(CustomQueryEngine):\n",
    "    \"\"\"RAG Query Engine.\"\"\"\n",
    "\n",
    "    \n",
    "    response_synthesizer: BaseSynthesizer\n",
    "\n",
    "    def custom_query(self, query_str: str):\n",
    "        nodes = get_retrieved_nodes(\n",
    "                        query_str,\n",
    "                        vector_top_k=30,\n",
    "                        reranker_top_n=5,\n",
    "                        with_reranker=False,\n",
    "                    )\n",
    "        response_obj = self.response_synthesizer.synthesize(query_str, nodes)\n",
    "        return response_obj\n",
    "    \n",
    "synthesizer = get_response_synthesizer(response_mode=\"compact\")\n",
    "query_engine = RAGQueryEngine(\n",
    "    response_synthesizer=synthesizer\n",
    ")\n",
    "\n",
    "response = query_engine.query(\"What are potential CONSECUENCES of keytruda?\")\n",
    "response\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 220 entries, 0 to 219\n",
      "Data columns (total 23 columns):\n",
      " #   Column                     Non-Null Count  Dtype         \n",
      "---  ------                     --------------  -----         \n",
      " 0   Unnamed: 0                 220 non-null    int64         \n",
      " 1   Country                    220 non-null    object        \n",
      " 2   Requester_Type             220 non-null    object        \n",
      " 3   Product                    220 non-null    object        \n",
      " 4   Indication                 220 non-null    object        \n",
      " 5   Question                   220 non-null    object        \n",
      " 6   Channel                    220 non-null    object        \n",
      " 7   Date_Time_Open             220 non-null    datetime64[ns]\n",
      " 8   Date_Time_Closed           220 non-null    datetime64[ns]\n",
      " 9   Answer_Solution            220 non-null    object        \n",
      " 10  Duration                   220 non-null    int64         \n",
      " 11  Day_of_Week                220 non-null    object        \n",
      " 12  Week_Number                220 non-null    int64         \n",
      " 13  Month                      220 non-null    object        \n",
      " 14  Year                       220 non-null    int64         \n",
      " 15  text                       220 non-null    object        \n",
      " 16  Question_embedding         220 non-null    object        \n",
      " 17  Answer_Solution_embedding  220 non-null    object        \n",
      " 18  text_embedding             220 non-null    object        \n",
      " 19  text_cluster               220 non-null    int64         \n",
      " 20  question_cluster           220 non-null    int64         \n",
      " 21  answer_cluster             220 non-null    int64         \n",
      " 22  augmented_questions        220 non-null    object        \n",
      "dtypes: datetime64[ns](2), int64(7), object(14)\n",
      "memory usage: 39.7+ KB\n"
     ]
    }
   ],
   "source": [
    "df = pd.read_parquet(\"../data/processed_data/df_eval.parquet\")\n",
    "df.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "INFO:httpx:HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"\n",
      "INFO:httpx:HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"\n",
      "HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "Response(response='Common adverse reactions associated with Keytruda include fatigue, nausea, skin rash, colitis, hepatitis, pneumonitis, cough, chest pain, changes in vision, itching, diarrhea, and fluctuations in blood pressure.', source_nodes=[NodeWithScore(node=TextNode(id_='1c86f3e8-53f4-417a-9c1b-81fb42255e97', embedding=None, metadata={'document_title': 'Keytruda and Immune-Related Adverse Effects: A Comprehensive Overview'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='49de588d-beb9-4e7e-84dc-06ffb2e63a2d', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='c73be1b4e2cb5e6157fd80000f0fe59f6ca8631fa4924c5ed0be7dd3180c3218')}, text='Can Keytruda cause immune-related adverse effects? Yes, Keytruda can cause immune-related adverse effects such as colitis, hepatitis, and pneumonitis.', mimetype='text/plain', start_char_idx=0, end_char_idx=150, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6819386237672924), NodeWithScore(node=TextNode(id_='6e3d4a37-d467-4472-8c26-d04a1f5bf215', embedding=None, metadata={'document_title': 'Common Side Effects of Keytruda: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='a800f0aa-054f-4ed7-8ab4-7931c0b9b874', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='e5a39cfff146f563f89b2818c0eff8c96284c5f2ef84443f0245b56e5852daf4')}, text='What are the common side effects of Keytruda? Common side effects include fatigue, nausea, and skin rash.', mimetype='text/plain', start_char_idx=0, end_char_idx=105, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6454340255797105), NodeWithScore(node=TextNode(id_='08a41277-3e68-438d-a1ef-0e5cee2fee19', embedding=None, metadata={'document_title': 'Keytruda Treatment: Reporting Symptoms Immediately for Optimal Care and Safety'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='036d6935-3d22-4899-8e00-187bc1f19455', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='ece4cc1d01c5ca9149d1021a1bef61325dc0d0ddc383e236acdc57517e0e59cf')}, text='What should patients report immediately while on Keytruda treatment? Patients should report any new or worsening symptoms such as cough, chest pain, or changes in vision immediately.', mimetype='text/plain', start_char_idx=0, end_char_idx=182, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6199617115159429), NodeWithScore(node=TextNode(id_='42490fd1-3472-46b2-a045-3c674b8c4d45', embedding=None, metadata={'document_title': 'Monitoring Keytruda Side Effects in NSCLC Patients: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='e6afb036-e8de-4798-ac85-b11e7126d096', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='c836b84f73a24eb1651123703374f4762bd0bd27f62b0153ea405e07244ce7ef')}, text='Are there specific side effects of Keytruda that NSCLC patients should monitor? NSCLC patients should monitor for cough, shortness of breath, and chest pain, as these could indicate immune-related pneumonitis.', mimetype='text/plain', start_char_idx=0, end_char_idx=209, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6081714205401847), NodeWithScore(node=TextNode(id_='5f426814-a97f-444e-9e11-ae49bfd754d0', embedding=None, metadata={'document_title': 'Side Effects in KEYNOTE-006 Trial: A Comprehensive Analysis'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='e679712a-9d64-446e-8392-a8119382e131', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='52217f9f5838b33448bea23a48004bd2620c4e6e5da0e6ef582fb74435b671ff')}, text='What were the side effects noted in the KEYNOTE-006 trial? Common side effects included fatigue, itching, and diarrhea.', mimetype='text/plain', start_char_idx=0, end_char_idx=119, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6063534950794569), NodeWithScore(node=TextNode(id_='82c7d105-9423-4af9-b9e9-e48a1b5c87f8', embedding=None, metadata={'document_title': 'Keytruda Use in NSCLC Patients with Autoimmune Diseases: Caution Advised'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='d2d6ade0-d86c-441f-9bae-6d22c5400925', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='d6006a9d9525d8f9c40c21e1768057a9ab8ebe753bb9f9b1fbe831a9c6b62979')}, text='Can Keytruda be used in NSCLC patients with autoimmune diseases? Keytruda should be used with caution in patients with pre-existing autoimmune diseases due to the risk of exacerbating the condition.', mimetype='text/plain', start_char_idx=0, end_char_idx=198, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5784545989225002), NodeWithScore(node=TextNode(id_='eea58cb1-6d6b-48bf-8477-760409f4047d', embedding=None, metadata={'document_title': 'Interactions of Keytruda with Steroids and Immunosuppressants: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='987f65cf-e7fa-426b-9dee-bcb319fbd0eb', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='1647b8ddf165cd4ee7bacab5592a24b4855623ccc473132a13c588692b32adef')}, text='Are there any known interactions between Keytruda and other medications? Yes, Keytruda can interact with steroids and certain immunosuppressants, potentially affecting its efficacy and safety.', mimetype='text/plain', start_char_idx=0, end_char_idx=192, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5756575453142698), NodeWithScore(node=TextNode(id_='64096ccf-4e98-4416-86cb-b1d896231199', embedding=None, metadata={'document_title': 'Keytruda and Blood Pressure Changes: Understanding the Relationship and Implications'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='2033f1e0-dbd3-4838-b607-3a9a2d3f8844', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='4b18e3384a842ce815e6bdce35bf79b0fff938dc138b2aea40bc50b5703eb955')}, text='Can Keytruda cause changes in blood pressure? Yes, fluctuations in blood pressure can occur, and patients should monitor their blood pressure regularly.', mimetype='text/plain', start_char_idx=0, end_char_idx=152, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5743277461011242), NodeWithScore(node=TextNode(id_='6769e1e6-7182-41b8-9f5a-498971f6a7ab', embedding=None, metadata={'document_title': \"Keytruda's Dual Impact on Immune System Function in Non-Small Cell Lung Cancer Patients: A Comprehensive Review\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='47b3ef42-c71e-4a91-8814-d07937aae69e', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='e12b51245aa4983a9f49193844a23111cb167b4b00c8d446eb4db98f97a74af8')}, text=\"How does Keytruda affect immune system function in NSCLC patients? Keytruda enhances the immune system's ability to detect and destroy cancer cells but can also lead to immune-related adverse effects that need to be managed.\", mimetype='text/plain', start_char_idx=0, end_char_idx=224, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5681061507524874), NodeWithScore(node=TextNode(id_='7dbe67da-6f12-4c72-b628-73539e76d315', embedding=None, metadata={'document_title': 'Treatment of NSCLC Patients with Brain Metastases Using Keytruda: Importance of Close Monitoring for Neurological Symptoms'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='48e47199-0c64-40eb-a474-2ef74addbaec', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='473c19f8e08f4dad458c9324b04d890d68b306b29eedf95c765f6305256b0652')}, text='Can NSCLC patients with brain metastases be treated with Keytruda? Keytruda can be used in NSCLC patients with brain metastases, especially when systemic disease control is needed, but close monitoring for neurological symptoms is essential.', mimetype='text/plain', start_char_idx=0, end_char_idx=241, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5518921025239342), NodeWithScore(node=TextNode(id_='51cbfd01-e017-42de-a362-35deae677033', embedding=None, metadata={'document_title': 'Monitoring Protocols for NSCLC Patients on Keytruda: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='998066fe-4f64-4047-81ec-e5f27c9c8b71', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='8ece3cf9c35dc00341732316c58b9e50d78e2c1e752cb31e55dc92bfdfd0598d')}, text='Are there any specific monitoring protocols for NSCLC patients on Keytruda as suggested by KEYNOTE-006 outcomes? Regular monitoring of liver function, lung function, and immune markers is recommended to manage potential side effects effectively.', mimetype='text/plain', start_char_idx=0, end_char_idx=245, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5504142318040156), NodeWithScore(node=TextNode(id_='7e5d5dcc-7c95-4fbe-ba74-037aa6e41ca3', embedding=None, metadata={'document_title': 'Safety of Keytruda in Pregnancy: A Comprehensive Review'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='e2873838-e865-4cad-9d6f-5cdf0f2db7d2', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='583eb4caa1acdd76a69a5a2568c582a8d1b24bf01b5232055a763bb6cd4b00a1')}, text='Is Keytruda safe for pregnant women? Keytruda is not recommended for use during pregnancy due to potential risks to the fetus.', mimetype='text/plain', start_char_idx=0, end_char_idx=126, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5352512262265081), NodeWithScore(node=TextNode(id_='ff00c4a3-45e0-425e-8ea7-5a08a272c9d1', embedding=None, metadata={'document_title': 'Keytruda Treatment Response Rate in Melanoma Patients: A Comprehensive Review'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='1076524e-02d4-4afd-b5c7-41e4890f7b11', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='eeb978316d5f07d2b6c828a5ab96c5fb04c5a0dde90346ba8100320f7035a8ca')}, text='What is the response rate of melanoma patients treated with Keytruda? Approximately 40% of melanoma patients respond positively to Keytruda treatment.', mimetype='text/plain', start_char_idx=0, end_char_idx=150, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5262940313805486), NodeWithScore(node=TextNode(id_='9410a4fa-12e0-49d0-9a10-27cbad12b258', embedding=None, metadata={'document_title': 'Keytruda and Fatigue in NSCLC Patients: Understanding the Impact of Immunotherapy on Energy Levels'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='8a33e7be-bb66-46e6-aee0-81fe1bd2011b', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='b1e1969e11c284e71c9f2530c3e448ec900cd1a9391f7507ede56fd3401224f1')}, text='Can Keytruda cause fatigue in NSCLC patients? No detailed information aviable on the given topic.', mimetype='text/plain', start_char_idx=0, end_char_idx=97, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5254205653877505), NodeWithScore(node=TextNode(id_='0f9aa112-e9e2-48df-87db-23cbbba2b38f', embedding=None, metadata={'document_title': 'Keytruda Administration: Comprehensive Guide for Intravenous Infusion Over 30 Minutes'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='90836c65-0674-4663-867f-576e0068569a', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='1b49e5c862a94574d8068d5c00457f2698e05dd8c98cec8ee3c68720053a7ba9')}, text='How is Keytruda administered? Keytruda is administered as an intravenous infusion over 30 minutes.', mimetype='text/plain', start_char_idx=0, end_char_idx=98, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5203420657339662), NodeWithScore(node=TextNode(id_='0cd2c9ce-7345-42dd-bebe-648a3d83d682', embedding=None, metadata={'document_title': 'Positive Response to Keytruda in NSCLC: Tumor Size Reduction, Respiratory Symptom Improvement, and Increased Well-Being in Patients with Non-Small Cell Lung Cancer'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='c5455699-72e7-4ac1-9219-e52b248fd229', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='88c382ad9222a2052c23403c6568abb17f7fa4f31c9e97c68ca8c67f56e5753f')}, text='What are the signs of a positive response to Keytruda in NSCLC? Signs include a decrease in tumor size on imaging, improvement in respiratory symptoms, and increased overall physical activity and well-being.', mimetype='text/plain', start_char_idx=0, end_char_idx=207, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5200200536803029), NodeWithScore(node=TextNode(id_='31dbb54c-b740-40f5-9f86-15b05aafecf9', embedding=None, metadata={'document_title': 'Keytruda Dosage Recommendations for Melanoma Treatment'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='642f3089-69ce-452c-afd7-ab2f6ad29f88', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='398aec4e73b60ec219102c812038d8f71b49e6f1289cdd58ee8d1f40b515e6de')}, text='What is the recommended dosage of Keytruda for melanoma? The recommended dosage is 200 mg every three weeks for adults.', mimetype='text/plain', start_char_idx=0, end_char_idx=119, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5156465474606022), NodeWithScore(node=TextNode(id_='8c1e8f5a-13b3-4097-92ed-918c596df1ac', embedding=None, metadata={'document_title': \"Keytruda's Effectiveness in Various Cancer Types: A Comprehensive Review\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='3eeccdc7-8fe1-4c2f-b3ce-c805269deea5', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='211fd7fe5d712aa71ad65225538e8c34784a890315e2295a6f2d3c0ec5b2a05c')}, text='Does Keytruda work for all types of cancer? Keytruda is most effective in cancers that express PD-L1 and in a genetic background favorable to immune therapy.', mimetype='text/plain', start_char_idx=0, end_char_idx=157, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5082851783118757), NodeWithScore(node=TextNode(id_='cb5773a5-e9fa-43cd-a852-25da66db70e2', embedding=None, metadata={'document_title': 'Comprehensive Patient Education on Keytruda: Understanding the Benefits, Risks, and Follow-Up Care'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='03af9a2f-372c-4bc6-8b4c-86f2e38f5588', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='686b693be1f48bc18db21fcd4a928c3180cd73f4745d4dfd26a532a14c46aa5a')}, text='How do healthcare providers educate patients about the benefits and risks of Keytruda? Healthcare providers offer educational materials, detailed consultations, and regular follow-up to discuss treatment progress and side effects.', mimetype='text/plain', start_char_idx=0, end_char_idx=230, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5016025570584757), NodeWithScore(node=TextNode(id_='a3e4ba87-85d6-4b7f-b38e-261a733cdfb8', embedding=None, metadata={'document_title': \"Keytruda's Impact on Metastatic NSCLC: Progression Reduction and Survival Improvement in Patients\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='172b6ea5-2346-4c47-9f4e-c6cd77f83ba4', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='a09dfd6a82cdfee88b2c5772f18613aa634b9ec8cbb9de170d6db265970189f4')}, text='What was the impact of Keytruda on metastatic NSCLC in the KEYNOTE-051 trial? Keytruda significantly reduced the progression of metastatic disease and improved survival rates in metastatic NSCLC patients.', mimetype='text/plain', start_char_idx=0, end_char_idx=204, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5012127234942816), NodeWithScore(node=TextNode(id_='c327f89d-31c2-4eef-909c-ad11bf2ce74a', embedding=None, metadata={'document_title': 'Criteria for Discontinuing Keytruda in Non-Small Cell Lung Cancer Patients: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='2f328ea4-c5a8-4320-b88f-2ca1cbe2911b', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='32af240e9f1d3da212ca6def5a4e93468a5c04d3f38f989501f5131ec2761d9e')}, text='What are the criteria for discontinuing Keytruda in NSCLC patients? Keytruda may be discontinued if there is significant disease progression, unacceptable toxicity, or upon patient decision in consultation with their healthcare provider.', mimetype='text/plain', start_char_idx=0, end_char_idx=237, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.4999092788744523), NodeWithScore(node=TextNode(id_='5f013f4e-d7c3-4183-8bb3-7a47a4fa5247', embedding=None, metadata={'document_title': '\"Keytruda: Rapid Effects in Cancer Treatment - A Comprehensive Overview\"'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='5e1cc82f-8dfd-4ed1-a328-f65bd5fc0d35', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='e603b5a6c3801d39d0f5cf61121c09f7b5b31749c5814f1b476627cdd8084a6e')}, text='How long does it take to see the effects of Keytruda in treating cancer? Some patients may see effects as early as 2 to 3 months into the treatment.', mimetype='text/plain', start_char_idx=0, end_char_idx=148, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.4966397456139734), NodeWithScore(node=TextNode(id_='39aa151b-376f-4262-8d54-55600a323763', embedding=None, metadata={'document_title': 'Combination Therapies with Keytruda for Enhanced Cancer Treatment: A Comprehensive Overview'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='433dd35b-1d97-4c68-9594-545629b5b4f3', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='12a8d2b371d47dda014ac33af341be6d82415dd681b26dececc4838a7f330600')}, text='Can Keytruda be used in combination with other therapies? Yes, Keytruda can be used in combination with chemotherapy and other immunotherapies depending on the cancer type.', mimetype='text/plain', start_char_idx=0, end_char_idx=172, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.49495759104940334), NodeWithScore(node=TextNode(id_='5e304353-3439-461b-91ab-639a11bf7dae', embedding=None, metadata={'document_title': 'Keytruda Support Community: Sharing Experiences and Advice'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='7ec77fae-086c-43bb-a92e-91c1d4d435e7', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='eb3f5ae6f374cc93ba105088a7e6f71e15ade3db30aaacc0daa77a017231d428')}, text='Is there a community support group for patients undergoing treatment with Keytruda? Yes, several online and local support groups are available for sharing experiences and advice.', mimetype='text/plain', start_char_idx=0, end_char_idx=178, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.494241779629769), NodeWithScore(node=TextNode(id_='0111506d-006c-48b7-9ba2-7038fc2f4424', embedding=None, metadata={'document_title': 'Enhancing NSCLC Treatment with Keytruda Combination Therapy: A Comprehensive Review'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='58484f72-869e-4623-8e75-af551586f3e0', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='0d5b90b6f05e5f043dcfe0b79950ef0294571dfc808c9fc452ff3dbf368de11e')}, text='How does Keytruda work in combination with other therapies for NSCLC?  Keytruda works synergistically with chemotherapy and other immunotherapies to enhance the immune response against cancer cells, often leading to improved outcomes.', mimetype='text/plain', start_char_idx=0, end_char_idx=234, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.49104664323378566), NodeWithScore(node=TextNode(id_='85550009-23c9-4640-850f-4898397a3f59', embedding=None, metadata={'document_title': 'The Impact of Keytruda on Survival Rates in Non-Small Cell Lung Cancer Patients with PD-L1 Expression'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='4def5d5e-7e3a-4924-aa4d-1f1471c79b90', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='c94df6025cefcf1493fb5461c551250192d9938b7a0b3fae81bbd7dd0dfa9dd6')}, text='How effective is Keytruda in treating non-small cell lung cancer? Keytruda has shown to improve survival rates significantly in non-small cell lung cancer patients with PD-L1 expression.', mimetype='text/plain', start_char_idx=0, end_char_idx=186, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.4884533559892855), NodeWithScore(node=TextNode(id_='aa0b8a1a-6bf8-45de-87a9-369873d76e93', embedding=None, metadata={'document_title': \"Guidelines for Keytruda in the Treatment of Hodgkin's Lymphoma\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='621e90d2-0989-4dd8-bd94-cbedad0d4aac', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='74ca0cad5d3066e93179bf0032fa6ddfd1525d1d506296b91f301f7b1c92b67d')}, text=\"What are the guidelines for Keytruda in treating Hodgkin's lymphoma? Keytruda is recommended for relapsed or refractory classical Hodgkin lymphoma after two or more lines of therapy.\", mimetype='text/plain', start_char_idx=0, end_char_idx=182, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.4857030522872945), NodeWithScore(node=TextNode(id_='c3df4d91-a194-4217-95e1-ce3522c6560f', embedding=None, metadata={'document_title': \"Keytruda's Superiority in Improving Survival Rates for NSCLC Patients with High PD-L1 Expression: A Comprehensive Analysis\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='ec5f23e6-e468-4d61-a9bb-36dfecc2b72f', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='3b1dad66a83bd670df1e309367e273229a37f197a7c87c715f495efc3276e4e9')}, text='How does Keytruda improve survival rates in NSCLC patients compared to traditional treatments? Keytruda has been shown to improve the overall survival rates by reducing the risk of death by about 40% compared to traditional chemotherapy in patients with high PD-L1 expression.', mimetype='text/plain', start_char_idx=0, end_char_idx=276, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.483642120959408), NodeWithScore(node=TextNode(id_='b139d3ef-12b2-4f0f-9254-d72f61f599d9', embedding=None, metadata={'document_title': \"Keytruda's Five-Year Survival Rate for Lung Cancer Patients: A Comprehensive Review\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='8a302781-7928-4a1e-bf15-e860c40adde6', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='cc5f7e805e3eb8dc3bac1c5bb409348154aa1b6ea31e5ed498c08c45fea6ed1b')}, text='What is the five-year survival rate for patients using Keytruda for lung cancer? No detailed information aviable on the given topic.', mimetype='text/plain', start_char_idx=0, end_char_idx=132, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.47820969645495426), NodeWithScore(node=TextNode(id_='97487298-d1d4-48d8-a8fd-ba01fcdc550f', embedding=None, metadata={'document_title': 'Complete Remission Rates in Non-Small Cell Lung Cancer Patients Treated with Keytruda in the KEYNOTE-789 Trial'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='62a4558a-ea6f-4e0f-af2d-868668394ffc', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='a2c68d5dcd92454cc53cabee934ac6dfa762349d42542ff7609d9f1855dca2db')}, text='What percentage of NSCLC patients experienced complete remission with Keytruda treatment in KEYNOTE-789? The provided information do not offer detailed information on the topic or questions self.', mimetype='text/plain', start_char_idx=0, end_char_idx=195, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.471069436768638)], metadata={'1c86f3e8-53f4-417a-9c1b-81fb42255e97': {'document_title': 'Keytruda and Immune-Related Adverse Effects: A Comprehensive Overview'}, '6e3d4a37-d467-4472-8c26-d04a1f5bf215': {'document_title': 'Common Side Effects of Keytruda: A Comprehensive Guide'}, '08a41277-3e68-438d-a1ef-0e5cee2fee19': {'document_title': 'Keytruda Treatment: Reporting Symptoms Immediately for Optimal Care and Safety'}, '42490fd1-3472-46b2-a045-3c674b8c4d45': {'document_title': 'Monitoring Keytruda Side Effects in NSCLC Patients: A Comprehensive Guide'}, '5f426814-a97f-444e-9e11-ae49bfd754d0': {'document_title': 'Side Effects in KEYNOTE-006 Trial: A Comprehensive Analysis'}, '82c7d105-9423-4af9-b9e9-e48a1b5c87f8': {'document_title': 'Keytruda Use in NSCLC Patients with Autoimmune Diseases: Caution Advised'}, 'eea58cb1-6d6b-48bf-8477-760409f4047d': {'document_title': 'Interactions of Keytruda with Steroids and Immunosuppressants: A Comprehensive Guide'}, '64096ccf-4e98-4416-86cb-b1d896231199': {'document_title': 'Keytruda and Blood Pressure Changes: Understanding the Relationship and Implications'}, '6769e1e6-7182-41b8-9f5a-498971f6a7ab': {'document_title': \"Keytruda's Dual Impact on Immune System Function in Non-Small Cell Lung Cancer Patients: A Comprehensive Review\"}, '7dbe67da-6f12-4c72-b628-73539e76d315': {'document_title': 'Treatment of NSCLC Patients with Brain Metastases Using Keytruda: Importance of Close Monitoring for Neurological Symptoms'}, '51cbfd01-e017-42de-a362-35deae677033': {'document_title': 'Monitoring Protocols for NSCLC Patients on Keytruda: A Comprehensive Guide'}, '7e5d5dcc-7c95-4fbe-ba74-037aa6e41ca3': {'document_title': 'Safety of Keytruda in Pregnancy: A Comprehensive Review'}, 'ff00c4a3-45e0-425e-8ea7-5a08a272c9d1': {'document_title': 'Keytruda Treatment Response Rate in Melanoma Patients: A Comprehensive Review'}, '9410a4fa-12e0-49d0-9a10-27cbad12b258': {'document_title': 'Keytruda and Fatigue in NSCLC Patients: Understanding the Impact of Immunotherapy on Energy Levels'}, '0f9aa112-e9e2-48df-87db-23cbbba2b38f': {'document_title': 'Keytruda Administration: Comprehensive Guide for Intravenous Infusion Over 30 Minutes'}, '0cd2c9ce-7345-42dd-bebe-648a3d83d682': {'document_title': 'Positive Response to Keytruda in NSCLC: Tumor Size Reduction, Respiratory Symptom Improvement, and Increased Well-Being in Patients with Non-Small Cell Lung Cancer'}, '31dbb54c-b740-40f5-9f86-15b05aafecf9': {'document_title': 'Keytruda Dosage Recommendations for Melanoma Treatment'}, '8c1e8f5a-13b3-4097-92ed-918c596df1ac': {'document_title': \"Keytruda's Effectiveness in Various Cancer Types: A Comprehensive Review\"}, 'cb5773a5-e9fa-43cd-a852-25da66db70e2': {'document_title': 'Comprehensive Patient Education on Keytruda: Understanding the Benefits, Risks, and Follow-Up Care'}, 'a3e4ba87-85d6-4b7f-b38e-261a733cdfb8': {'document_title': \"Keytruda's Impact on Metastatic NSCLC: Progression Reduction and Survival Improvement in Patients\"}, 'c327f89d-31c2-4eef-909c-ad11bf2ce74a': {'document_title': 'Criteria for Discontinuing Keytruda in Non-Small Cell Lung Cancer Patients: A Comprehensive Guide'}, '5f013f4e-d7c3-4183-8bb3-7a47a4fa5247': {'document_title': '\"Keytruda: Rapid Effects in Cancer Treatment - A Comprehensive Overview\"'}, '39aa151b-376f-4262-8d54-55600a323763': {'document_title': 'Combination Therapies with Keytruda for Enhanced Cancer Treatment: A Comprehensive Overview'}, '5e304353-3439-461b-91ab-639a11bf7dae': {'document_title': 'Keytruda Support Community: Sharing Experiences and Advice'}, '0111506d-006c-48b7-9ba2-7038fc2f4424': {'document_title': 'Enhancing NSCLC Treatment with Keytruda Combination Therapy: A Comprehensive Review'}, '85550009-23c9-4640-850f-4898397a3f59': {'document_title': 'The Impact of Keytruda on Survival Rates in Non-Small Cell Lung Cancer Patients with PD-L1 Expression'}, 'aa0b8a1a-6bf8-45de-87a9-369873d76e93': {'document_title': \"Guidelines for Keytruda in the Treatment of Hodgkin's Lymphoma\"}, 'c3df4d91-a194-4217-95e1-ce3522c6560f': {'document_title': \"Keytruda's Superiority in Improving Survival Rates for NSCLC Patients with High PD-L1 Expression: A Comprehensive Analysis\"}, 'b139d3ef-12b2-4f0f-9254-d72f61f599d9': {'document_title': \"Keytruda's Five-Year Survival Rate for Lung Cancer Patients: A Comprehensive Review\"}, '97487298-d1d4-48d8-a8fd-ba01fcdc550f': {'document_title': 'Complete Remission Rates in Non-Small Cell Lung Cancer Patients Treated with Keytruda in the KEYNOTE-789 Trial'}})"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response_vector = query_engine.query(df[\"augmented_questions\"][0])\n",
    "\n",
    "response_vector"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Response(response='Common adverse reactions associated with Keytruda include fatigue, nausea, skin rash, colitis, hepatitis, pneumonitis, cough, chest pain, changes in vision, itching, diarrhea, and fluctuations in blood pressure.', source_nodes=[NodeWithScore(node=TextNode(id_='1c86f3e8-53f4-417a-9c1b-81fb42255e97', embedding=None, metadata={'document_title': 'Keytruda and Immune-Related Adverse Effects: A Comprehensive Overview'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='49de588d-beb9-4e7e-84dc-06ffb2e63a2d', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='c73be1b4e2cb5e6157fd80000f0fe59f6ca8631fa4924c5ed0be7dd3180c3218')}, text='Can Keytruda cause immune-related adverse effects? Yes, Keytruda can cause immune-related adverse effects such as colitis, hepatitis, and pneumonitis.', mimetype='text/plain', start_char_idx=0, end_char_idx=150, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6819386237672924), NodeWithScore(node=TextNode(id_='6e3d4a37-d467-4472-8c26-d04a1f5bf215', embedding=None, metadata={'document_title': 'Common Side Effects of Keytruda: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='a800f0aa-054f-4ed7-8ab4-7931c0b9b874', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='e5a39cfff146f563f89b2818c0eff8c96284c5f2ef84443f0245b56e5852daf4')}, text='What are the common side effects of Keytruda? Common side effects include fatigue, nausea, and skin rash.', mimetype='text/plain', start_char_idx=0, end_char_idx=105, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6454340255797105), NodeWithScore(node=TextNode(id_='08a41277-3e68-438d-a1ef-0e5cee2fee19', embedding=None, metadata={'document_title': 'Keytruda Treatment: Reporting Symptoms Immediately for Optimal Care and Safety'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='036d6935-3d22-4899-8e00-187bc1f19455', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='ece4cc1d01c5ca9149d1021a1bef61325dc0d0ddc383e236acdc57517e0e59cf')}, text='What should patients report immediately while on Keytruda treatment? Patients should report any new or worsening symptoms such as cough, chest pain, or changes in vision immediately.', mimetype='text/plain', start_char_idx=0, end_char_idx=182, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6199617115159429), NodeWithScore(node=TextNode(id_='42490fd1-3472-46b2-a045-3c674b8c4d45', embedding=None, metadata={'document_title': 'Monitoring Keytruda Side Effects in NSCLC Patients: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='e6afb036-e8de-4798-ac85-b11e7126d096', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='c836b84f73a24eb1651123703374f4762bd0bd27f62b0153ea405e07244ce7ef')}, text='Are there specific side effects of Keytruda that NSCLC patients should monitor? NSCLC patients should monitor for cough, shortness of breath, and chest pain, as these could indicate immune-related pneumonitis.', mimetype='text/plain', start_char_idx=0, end_char_idx=209, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6081714205401847), NodeWithScore(node=TextNode(id_='5f426814-a97f-444e-9e11-ae49bfd754d0', embedding=None, metadata={'document_title': 'Side Effects in KEYNOTE-006 Trial: A Comprehensive Analysis'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='e679712a-9d64-446e-8392-a8119382e131', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='52217f9f5838b33448bea23a48004bd2620c4e6e5da0e6ef582fb74435b671ff')}, text='What were the side effects noted in the KEYNOTE-006 trial? Common side effects included fatigue, itching, and diarrhea.', mimetype='text/plain', start_char_idx=0, end_char_idx=119, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.6063534950794569), NodeWithScore(node=TextNode(id_='82c7d105-9423-4af9-b9e9-e48a1b5c87f8', embedding=None, metadata={'document_title': 'Keytruda Use in NSCLC Patients with Autoimmune Diseases: Caution Advised'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='d2d6ade0-d86c-441f-9bae-6d22c5400925', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='d6006a9d9525d8f9c40c21e1768057a9ab8ebe753bb9f9b1fbe831a9c6b62979')}, text='Can Keytruda be used in NSCLC patients with autoimmune diseases? Keytruda should be used with caution in patients with pre-existing autoimmune diseases due to the risk of exacerbating the condition.', mimetype='text/plain', start_char_idx=0, end_char_idx=198, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5784545989225002), NodeWithScore(node=TextNode(id_='eea58cb1-6d6b-48bf-8477-760409f4047d', embedding=None, metadata={'document_title': 'Interactions of Keytruda with Steroids and Immunosuppressants: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='987f65cf-e7fa-426b-9dee-bcb319fbd0eb', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='1647b8ddf165cd4ee7bacab5592a24b4855623ccc473132a13c588692b32adef')}, text='Are there any known interactions between Keytruda and other medications? Yes, Keytruda can interact with steroids and certain immunosuppressants, potentially affecting its efficacy and safety.', mimetype='text/plain', start_char_idx=0, end_char_idx=192, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5756575453142698), NodeWithScore(node=TextNode(id_='64096ccf-4e98-4416-86cb-b1d896231199', embedding=None, metadata={'document_title': 'Keytruda and Blood Pressure Changes: Understanding the Relationship and Implications'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='2033f1e0-dbd3-4838-b607-3a9a2d3f8844', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='4b18e3384a842ce815e6bdce35bf79b0fff938dc138b2aea40bc50b5703eb955')}, text='Can Keytruda cause changes in blood pressure? Yes, fluctuations in blood pressure can occur, and patients should monitor their blood pressure regularly.', mimetype='text/plain', start_char_idx=0, end_char_idx=152, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5743277461011242), NodeWithScore(node=TextNode(id_='6769e1e6-7182-41b8-9f5a-498971f6a7ab', embedding=None, metadata={'document_title': \"Keytruda's Dual Impact on Immune System Function in Non-Small Cell Lung Cancer Patients: A Comprehensive Review\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='47b3ef42-c71e-4a91-8814-d07937aae69e', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='e12b51245aa4983a9f49193844a23111cb167b4b00c8d446eb4db98f97a74af8')}, text=\"How does Keytruda affect immune system function in NSCLC patients? Keytruda enhances the immune system's ability to detect and destroy cancer cells but can also lead to immune-related adverse effects that need to be managed.\", mimetype='text/plain', start_char_idx=0, end_char_idx=224, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5681061507524874), NodeWithScore(node=TextNode(id_='7dbe67da-6f12-4c72-b628-73539e76d315', embedding=None, metadata={'document_title': 'Treatment of NSCLC Patients with Brain Metastases Using Keytruda: Importance of Close Monitoring for Neurological Symptoms'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='48e47199-0c64-40eb-a474-2ef74addbaec', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='473c19f8e08f4dad458c9324b04d890d68b306b29eedf95c765f6305256b0652')}, text='Can NSCLC patients with brain metastases be treated with Keytruda? Keytruda can be used in NSCLC patients with brain metastases, especially when systemic disease control is needed, but close monitoring for neurological symptoms is essential.', mimetype='text/plain', start_char_idx=0, end_char_idx=241, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5518921025239342), NodeWithScore(node=TextNode(id_='51cbfd01-e017-42de-a362-35deae677033', embedding=None, metadata={'document_title': 'Monitoring Protocols for NSCLC Patients on Keytruda: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='998066fe-4f64-4047-81ec-e5f27c9c8b71', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='8ece3cf9c35dc00341732316c58b9e50d78e2c1e752cb31e55dc92bfdfd0598d')}, text='Are there any specific monitoring protocols for NSCLC patients on Keytruda as suggested by KEYNOTE-006 outcomes? Regular monitoring of liver function, lung function, and immune markers is recommended to manage potential side effects effectively.', mimetype='text/plain', start_char_idx=0, end_char_idx=245, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5504142318040156), NodeWithScore(node=TextNode(id_='7e5d5dcc-7c95-4fbe-ba74-037aa6e41ca3', embedding=None, metadata={'document_title': 'Safety of Keytruda in Pregnancy: A Comprehensive Review'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='e2873838-e865-4cad-9d6f-5cdf0f2db7d2', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='583eb4caa1acdd76a69a5a2568c582a8d1b24bf01b5232055a763bb6cd4b00a1')}, text='Is Keytruda safe for pregnant women? Keytruda is not recommended for use during pregnancy due to potential risks to the fetus.', mimetype='text/plain', start_char_idx=0, end_char_idx=126, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5352512262265081), NodeWithScore(node=TextNode(id_='ff00c4a3-45e0-425e-8ea7-5a08a272c9d1', embedding=None, metadata={'document_title': 'Keytruda Treatment Response Rate in Melanoma Patients: A Comprehensive Review'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='1076524e-02d4-4afd-b5c7-41e4890f7b11', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='eeb978316d5f07d2b6c828a5ab96c5fb04c5a0dde90346ba8100320f7035a8ca')}, text='What is the response rate of melanoma patients treated with Keytruda? Approximately 40% of melanoma patients respond positively to Keytruda treatment.', mimetype='text/plain', start_char_idx=0, end_char_idx=150, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5262940313805486), NodeWithScore(node=TextNode(id_='9410a4fa-12e0-49d0-9a10-27cbad12b258', embedding=None, metadata={'document_title': 'Keytruda and Fatigue in NSCLC Patients: Understanding the Impact of Immunotherapy on Energy Levels'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='8a33e7be-bb66-46e6-aee0-81fe1bd2011b', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='b1e1969e11c284e71c9f2530c3e448ec900cd1a9391f7507ede56fd3401224f1')}, text='Can Keytruda cause fatigue in NSCLC patients? No detailed information aviable on the given topic.', mimetype='text/plain', start_char_idx=0, end_char_idx=97, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5254205653877505), NodeWithScore(node=TextNode(id_='0f9aa112-e9e2-48df-87db-23cbbba2b38f', embedding=None, metadata={'document_title': 'Keytruda Administration: Comprehensive Guide for Intravenous Infusion Over 30 Minutes'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='90836c65-0674-4663-867f-576e0068569a', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='1b49e5c862a94574d8068d5c00457f2698e05dd8c98cec8ee3c68720053a7ba9')}, text='How is Keytruda administered? Keytruda is administered as an intravenous infusion over 30 minutes.', mimetype='text/plain', start_char_idx=0, end_char_idx=98, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5203420657339662), NodeWithScore(node=TextNode(id_='0cd2c9ce-7345-42dd-bebe-648a3d83d682', embedding=None, metadata={'document_title': 'Positive Response to Keytruda in NSCLC: Tumor Size Reduction, Respiratory Symptom Improvement, and Increased Well-Being in Patients with Non-Small Cell Lung Cancer'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='c5455699-72e7-4ac1-9219-e52b248fd229', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='88c382ad9222a2052c23403c6568abb17f7fa4f31c9e97c68ca8c67f56e5753f')}, text='What are the signs of a positive response to Keytruda in NSCLC? Signs include a decrease in tumor size on imaging, improvement in respiratory symptoms, and increased overall physical activity and well-being.', mimetype='text/plain', start_char_idx=0, end_char_idx=207, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5200200536803029), NodeWithScore(node=TextNode(id_='31dbb54c-b740-40f5-9f86-15b05aafecf9', embedding=None, metadata={'document_title': 'Keytruda Dosage Recommendations for Melanoma Treatment'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='642f3089-69ce-452c-afd7-ab2f6ad29f88', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='398aec4e73b60ec219102c812038d8f71b49e6f1289cdd58ee8d1f40b515e6de')}, text='What is the recommended dosage of Keytruda for melanoma? The recommended dosage is 200 mg every three weeks for adults.', mimetype='text/plain', start_char_idx=0, end_char_idx=119, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5156465474606022), NodeWithScore(node=TextNode(id_='8c1e8f5a-13b3-4097-92ed-918c596df1ac', embedding=None, metadata={'document_title': \"Keytruda's Effectiveness in Various Cancer Types: A Comprehensive Review\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='3eeccdc7-8fe1-4c2f-b3ce-c805269deea5', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='211fd7fe5d712aa71ad65225538e8c34784a890315e2295a6f2d3c0ec5b2a05c')}, text='Does Keytruda work for all types of cancer? Keytruda is most effective in cancers that express PD-L1 and in a genetic background favorable to immune therapy.', mimetype='text/plain', start_char_idx=0, end_char_idx=157, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5082851783118757), NodeWithScore(node=TextNode(id_='cb5773a5-e9fa-43cd-a852-25da66db70e2', embedding=None, metadata={'document_title': 'Comprehensive Patient Education on Keytruda: Understanding the Benefits, Risks, and Follow-Up Care'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='03af9a2f-372c-4bc6-8b4c-86f2e38f5588', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='686b693be1f48bc18db21fcd4a928c3180cd73f4745d4dfd26a532a14c46aa5a')}, text='How do healthcare providers educate patients about the benefits and risks of Keytruda? Healthcare providers offer educational materials, detailed consultations, and regular follow-up to discuss treatment progress and side effects.', mimetype='text/plain', start_char_idx=0, end_char_idx=230, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5016025570584757), NodeWithScore(node=TextNode(id_='a3e4ba87-85d6-4b7f-b38e-261a733cdfb8', embedding=None, metadata={'document_title': \"Keytruda's Impact on Metastatic NSCLC: Progression Reduction and Survival Improvement in Patients\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='172b6ea5-2346-4c47-9f4e-c6cd77f83ba4', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='a09dfd6a82cdfee88b2c5772f18613aa634b9ec8cbb9de170d6db265970189f4')}, text='What was the impact of Keytruda on metastatic NSCLC in the KEYNOTE-051 trial? Keytruda significantly reduced the progression of metastatic disease and improved survival rates in metastatic NSCLC patients.', mimetype='text/plain', start_char_idx=0, end_char_idx=204, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.5012127234942816), NodeWithScore(node=TextNode(id_='c327f89d-31c2-4eef-909c-ad11bf2ce74a', embedding=None, metadata={'document_title': 'Criteria for Discontinuing Keytruda in Non-Small Cell Lung Cancer Patients: A Comprehensive Guide'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='2f328ea4-c5a8-4320-b88f-2ca1cbe2911b', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='32af240e9f1d3da212ca6def5a4e93468a5c04d3f38f989501f5131ec2761d9e')}, text='What are the criteria for discontinuing Keytruda in NSCLC patients? Keytruda may be discontinued if there is significant disease progression, unacceptable toxicity, or upon patient decision in consultation with their healthcare provider.', mimetype='text/plain', start_char_idx=0, end_char_idx=237, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.4999092788744523), NodeWithScore(node=TextNode(id_='5f013f4e-d7c3-4183-8bb3-7a47a4fa5247', embedding=None, metadata={'document_title': '\"Keytruda: Rapid Effects in Cancer Treatment - A Comprehensive Overview\"'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='5e1cc82f-8dfd-4ed1-a328-f65bd5fc0d35', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='e603b5a6c3801d39d0f5cf61121c09f7b5b31749c5814f1b476627cdd8084a6e')}, text='How long does it take to see the effects of Keytruda in treating cancer? Some patients may see effects as early as 2 to 3 months into the treatment.', mimetype='text/plain', start_char_idx=0, end_char_idx=148, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.4966397456139734), NodeWithScore(node=TextNode(id_='39aa151b-376f-4262-8d54-55600a323763', embedding=None, metadata={'document_title': 'Combination Therapies with Keytruda for Enhanced Cancer Treatment: A Comprehensive Overview'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='433dd35b-1d97-4c68-9594-545629b5b4f3', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='12a8d2b371d47dda014ac33af341be6d82415dd681b26dececc4838a7f330600')}, text='Can Keytruda be used in combination with other therapies? Yes, Keytruda can be used in combination with chemotherapy and other immunotherapies depending on the cancer type.', mimetype='text/plain', start_char_idx=0, end_char_idx=172, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.49495759104940334), NodeWithScore(node=TextNode(id_='5e304353-3439-461b-91ab-639a11bf7dae', embedding=None, metadata={'document_title': 'Keytruda Support Community: Sharing Experiences and Advice'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='7ec77fae-086c-43bb-a92e-91c1d4d435e7', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='eb3f5ae6f374cc93ba105088a7e6f71e15ade3db30aaacc0daa77a017231d428')}, text='Is there a community support group for patients undergoing treatment with Keytruda? Yes, several online and local support groups are available for sharing experiences and advice.', mimetype='text/plain', start_char_idx=0, end_char_idx=178, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.494241779629769), NodeWithScore(node=TextNode(id_='0111506d-006c-48b7-9ba2-7038fc2f4424', embedding=None, metadata={'document_title': 'Enhancing NSCLC Treatment with Keytruda Combination Therapy: A Comprehensive Review'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='58484f72-869e-4623-8e75-af551586f3e0', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='0d5b90b6f05e5f043dcfe0b79950ef0294571dfc808c9fc452ff3dbf368de11e')}, text='How does Keytruda work in combination with other therapies for NSCLC?  Keytruda works synergistically with chemotherapy and other immunotherapies to enhance the immune response against cancer cells, often leading to improved outcomes.', mimetype='text/plain', start_char_idx=0, end_char_idx=234, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.49104664323378566), NodeWithScore(node=TextNode(id_='85550009-23c9-4640-850f-4898397a3f59', embedding=None, metadata={'document_title': 'The Impact of Keytruda on Survival Rates in Non-Small Cell Lung Cancer Patients with PD-L1 Expression'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='4def5d5e-7e3a-4924-aa4d-1f1471c79b90', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='c94df6025cefcf1493fb5461c551250192d9938b7a0b3fae81bbd7dd0dfa9dd6')}, text='How effective is Keytruda in treating non-small cell lung cancer? Keytruda has shown to improve survival rates significantly in non-small cell lung cancer patients with PD-L1 expression.', mimetype='text/plain', start_char_idx=0, end_char_idx=186, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.4884533559892855), NodeWithScore(node=TextNode(id_='aa0b8a1a-6bf8-45de-87a9-369873d76e93', embedding=None, metadata={'document_title': \"Guidelines for Keytruda in the Treatment of Hodgkin's Lymphoma\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='621e90d2-0989-4dd8-bd94-cbedad0d4aac', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='74ca0cad5d3066e93179bf0032fa6ddfd1525d1d506296b91f301f7b1c92b67d')}, text=\"What are the guidelines for Keytruda in treating Hodgkin's lymphoma? Keytruda is recommended for relapsed or refractory classical Hodgkin lymphoma after two or more lines of therapy.\", mimetype='text/plain', start_char_idx=0, end_char_idx=182, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.4857030522872945), NodeWithScore(node=TextNode(id_='c3df4d91-a194-4217-95e1-ce3522c6560f', embedding=None, metadata={'document_title': \"Keytruda's Superiority in Improving Survival Rates for NSCLC Patients with High PD-L1 Expression: A Comprehensive Analysis\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='ec5f23e6-e468-4d61-a9bb-36dfecc2b72f', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='3b1dad66a83bd670df1e309367e273229a37f197a7c87c715f495efc3276e4e9')}, text='How does Keytruda improve survival rates in NSCLC patients compared to traditional treatments? Keytruda has been shown to improve the overall survival rates by reducing the risk of death by about 40% compared to traditional chemotherapy in patients with high PD-L1 expression.', mimetype='text/plain', start_char_idx=0, end_char_idx=276, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.483642120959408), NodeWithScore(node=TextNode(id_='b139d3ef-12b2-4f0f-9254-d72f61f599d9', embedding=None, metadata={'document_title': \"Keytruda's Five-Year Survival Rate for Lung Cancer Patients: A Comprehensive Review\"}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='8a302781-7928-4a1e-bf15-e860c40adde6', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='cc5f7e805e3eb8dc3bac1c5bb409348154aa1b6ea31e5ed498c08c45fea6ed1b')}, text='What is the five-year survival rate for patients using Keytruda for lung cancer? No detailed information aviable on the given topic.', mimetype='text/plain', start_char_idx=0, end_char_idx=132, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.47820969645495426), NodeWithScore(node=TextNode(id_='97487298-d1d4-48d8-a8fd-ba01fcdc550f', embedding=None, metadata={'document_title': 'Complete Remission Rates in Non-Small Cell Lung Cancer Patients Treated with Keytruda in the KEYNOTE-789 Trial'}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={<NodeRelationship.SOURCE: '1'>: RelatedNodeInfo(node_id='62a4558a-ea6f-4e0f-af2d-868668394ffc', node_type=<ObjectType.DOCUMENT: '4'>, metadata={}, hash='a2c68d5dcd92454cc53cabee934ac6dfa762349d42542ff7609d9f1855dca2db')}, text='What percentage of NSCLC patients experienced complete remission with Keytruda treatment in KEYNOTE-789? The provided information do not offer detailed information on the topic or questions self.', mimetype='text/plain', start_char_idx=0, end_char_idx=195, text_template='[Excerpt from document]\\n{metadata_str}\\nExcerpt:\\n-----\\n{content}\\n-----\\n', metadata_template='{key}: {value}', metadata_seperator='\\n'), score=0.471069436768638)], metadata={'1c86f3e8-53f4-417a-9c1b-81fb42255e97': {'document_title': 'Keytruda and Immune-Related Adverse Effects: A Comprehensive Overview'}, '6e3d4a37-d467-4472-8c26-d04a1f5bf215': {'document_title': 'Common Side Effects of Keytruda: A Comprehensive Guide'}, '08a41277-3e68-438d-a1ef-0e5cee2fee19': {'document_title': 'Keytruda Treatment: Reporting Symptoms Immediately for Optimal Care and Safety'}, '42490fd1-3472-46b2-a045-3c674b8c4d45': {'document_title': 'Monitoring Keytruda Side Effects in NSCLC Patients: A Comprehensive Guide'}, '5f426814-a97f-444e-9e11-ae49bfd754d0': {'document_title': 'Side Effects in KEYNOTE-006 Trial: A Comprehensive Analysis'}, '82c7d105-9423-4af9-b9e9-e48a1b5c87f8': {'document_title': 'Keytruda Use in NSCLC Patients with Autoimmune Diseases: Caution Advised'}, 'eea58cb1-6d6b-48bf-8477-760409f4047d': {'document_title': 'Interactions of Keytruda with Steroids and Immunosuppressants: A Comprehensive Guide'}, '64096ccf-4e98-4416-86cb-b1d896231199': {'document_title': 'Keytruda and Blood Pressure Changes: Understanding the Relationship and Implications'}, '6769e1e6-7182-41b8-9f5a-498971f6a7ab': {'document_title': \"Keytruda's Dual Impact on Immune System Function in Non-Small Cell Lung Cancer Patients: A Comprehensive Review\"}, '7dbe67da-6f12-4c72-b628-73539e76d315': {'document_title': 'Treatment of NSCLC Patients with Brain Metastases Using Keytruda: Importance of Close Monitoring for Neurological Symptoms'}, '51cbfd01-e017-42de-a362-35deae677033': {'document_title': 'Monitoring Protocols for NSCLC Patients on Keytruda: A Comprehensive Guide'}, '7e5d5dcc-7c95-4fbe-ba74-037aa6e41ca3': {'document_title': 'Safety of Keytruda in Pregnancy: A Comprehensive Review'}, 'ff00c4a3-45e0-425e-8ea7-5a08a272c9d1': {'document_title': 'Keytruda Treatment Response Rate in Melanoma Patients: A Comprehensive Review'}, '9410a4fa-12e0-49d0-9a10-27cbad12b258': {'document_title': 'Keytruda and Fatigue in NSCLC Patients: Understanding the Impact of Immunotherapy on Energy Levels'}, '0f9aa112-e9e2-48df-87db-23cbbba2b38f': {'document_title': 'Keytruda Administration: Comprehensive Guide for Intravenous Infusion Over 30 Minutes'}, '0cd2c9ce-7345-42dd-bebe-648a3d83d682': {'document_title': 'Positive Response to Keytruda in NSCLC: Tumor Size Reduction, Respiratory Symptom Improvement, and Increased Well-Being in Patients with Non-Small Cell Lung Cancer'}, '31dbb54c-b740-40f5-9f86-15b05aafecf9': {'document_title': 'Keytruda Dosage Recommendations for Melanoma Treatment'}, '8c1e8f5a-13b3-4097-92ed-918c596df1ac': {'document_title': \"Keytruda's Effectiveness in Various Cancer Types: A Comprehensive Review\"}, 'cb5773a5-e9fa-43cd-a852-25da66db70e2': {'document_title': 'Comprehensive Patient Education on Keytruda: Understanding the Benefits, Risks, and Follow-Up Care'}, 'a3e4ba87-85d6-4b7f-b38e-261a733cdfb8': {'document_title': \"Keytruda's Impact on Metastatic NSCLC: Progression Reduction and Survival Improvement in Patients\"}, 'c327f89d-31c2-4eef-909c-ad11bf2ce74a': {'document_title': 'Criteria for Discontinuing Keytruda in Non-Small Cell Lung Cancer Patients: A Comprehensive Guide'}, '5f013f4e-d7c3-4183-8bb3-7a47a4fa5247': {'document_title': '\"Keytruda: Rapid Effects in Cancer Treatment - A Comprehensive Overview\"'}, '39aa151b-376f-4262-8d54-55600a323763': {'document_title': 'Combination Therapies with Keytruda for Enhanced Cancer Treatment: A Comprehensive Overview'}, '5e304353-3439-461b-91ab-639a11bf7dae': {'document_title': 'Keytruda Support Community: Sharing Experiences and Advice'}, '0111506d-006c-48b7-9ba2-7038fc2f4424': {'document_title': 'Enhancing NSCLC Treatment with Keytruda Combination Therapy: A Comprehensive Review'}, '85550009-23c9-4640-850f-4898397a3f59': {'document_title': 'The Impact of Keytruda on Survival Rates in Non-Small Cell Lung Cancer Patients with PD-L1 Expression'}, 'aa0b8a1a-6bf8-45de-87a9-369873d76e93': {'document_title': \"Guidelines for Keytruda in the Treatment of Hodgkin's Lymphoma\"}, 'c3df4d91-a194-4217-95e1-ce3522c6560f': {'document_title': \"Keytruda's Superiority in Improving Survival Rates for NSCLC Patients with High PD-L1 Expression: A Comprehensive Analysis\"}, 'b139d3ef-12b2-4f0f-9254-d72f61f599d9': {'document_title': \"Keytruda's Five-Year Survival Rate for Lung Cancer Patients: A Comprehensive Review\"}, '97487298-d1d4-48d8-a8fd-ba01fcdc550f': {'document_title': 'Complete Remission Rates in Non-Small Cell Lung Cancer Patients Treated with Keytruda in the KEYNOTE-789 Trial'}})"
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response_vector"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "from ragas.metrics import (\n",
    "    faithfulness,\n",
    "    answer_relevancy,\n",
    "    context_precision,\n",
    "    context_recall,\n",
    ")\n",
    "#from ragas.metrics.critique import harmfulness\n",
    "\n",
    "metrics = [\n",
    "    faithfulness,\n",
    "    answer_relevancy,\n",
    "    #context_precision,\n",
    "    #context_recall,\n",
    "    #harmfulness,\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [],
   "source": [
    "from llama_index.llms.openai import OpenAI\n",
    "from llama_index.embeddings.openai import OpenAIEmbedding\n",
    "\n",
    "# using GPT 3.5, use GPT 4 / 4-turbo for better accuracy\n",
    "evaluator_llm = OpenAI(model=\"gpt-3.5-turbo\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['What are the frequently encountered adverse reactions associated with Keytruda?',\n",
       " 'Which side effects are typically seen in patients receiving Keytruda therapy?',\n",
       " 'What are the usual side effects that individuals may experience when using Keytruda?',\n",
       " 'How common are the side effects reported with Keytruda treatment?',\n",
       " 'What are the expected side effects that patients may encounter while taking Keytruda?',\n",
       " 'Are immune-related adverse effects a potential risk associated with Keytruda?',\n",
       " 'Can Keytruda lead to adverse effects related to the immune system?',\n",
       " 'What immune-related adverse effects may arise from Keytruda treatment?',\n",
       " 'Is there a possibility of immune-related side effects occurring with Keytruda use?',\n",
       " 'What immune system complications can be caused by Keytruda?',\n",
       " 'What is the safety profile of Keytruda in pregnant women?',\n",
       " 'Are there any risks associated with using Keytruda during pregnancy?',\n",
       " 'Is Keytruda considered safe for pregnant patients based on current medical knowledge?',\n",
       " 'What are the potential effects of Keytruda on pregnant women and their unborn babies?',\n",
       " 'What precautions should pregnant women take if considering Keytruda treatment?',\n",
       " 'Which symptoms should patients promptly report when undergoing Keytruda therapy?',\n",
       " 'What signs require immediate attention from patients receiving Keytruda?',\n",
       " 'What specific conditions warrant immediate reporting by patients on Keytruda treatment?',\n",
       " 'When should patients on Keytruda therapy seek urgent medical advice?',\n",
       " 'Which changes in health status should patients on Keytruda promptly communicate to their healthcare provider?',\n",
       " 'What potential drug interactions should be considered when using Keytruda?',\n",
       " 'Are there specific medications that may interact with Keytruda?',\n",
       " 'Which other drugs can have interactions with Keytruda?',\n",
       " 'What are the risks of combining Keytruda with other medications?',\n",
       " 'How important is it to be aware of possible drug interactions with Keytruda?',\n",
       " 'What is the efficacy of Keytruda in the treatment of non-small cell lung cancer?',\n",
       " 'In what way does Keytruda demonstrate effectiveness in non-small cell lung cancer therapy?',\n",
       " 'What level of effectiveness does Keytruda exhibit when used for non-small cell lung cancer?',\n",
       " 'How successful is Keytruda as a treatment option for non-small cell lung cancer?',\n",
       " 'What is the effectiveness rate of Keytruda in non-small cell lung cancer patients?',\n",
       " 'What is the efficacy rate of Keytruda in treating melanoma patients?',\n",
       " 'How effective is Keytruda in producing responses in patients with melanoma?',\n",
       " 'What percentage of melanoma patients show a positive response to Keytruda treatment?',\n",
       " 'What is the rate of tumor response in melanoma patients receiving Keytruda?',\n",
       " 'How successful is Keytruda in eliciting responses from patients with melanoma?',\n",
       " 'Is Keytruda effective in treating various types of cancer?',\n",
       " 'For which types of cancer is Keytruda known to be effective?',\n",
       " 'Are there specific cancer types that respond well to Keytruda treatment?',\n",
       " 'In what types of cancer has Keytruda shown efficacy?',\n",
       " 'Which cancer types have shown positive outcomes with Keytruda therapy?',\n",
       " 'What is the typical timeframe for observing the therapeutic effects of Keytruda in cancer treatment?',\n",
       " 'When can patients expect to notice the impact of Keytruda on their cancer after starting treatment?',\n",
       " 'How soon do the effects of Keytruda become apparent in the treatment of cancer?',\n",
       " 'What is the usual duration before patients see the effects of Keytruda in combating cancer?',\n",
       " 'At what point in the treatment process do the effects of Keytruda typically manifest in cancer patients?',\n",
       " 'What is the long-term survival outcome for lung cancer patients treated with Keytruda over five years?',\n",
       " 'How does the five-year survival rate compare between lung cancer patients receiving Keytruda and those on other treatments?',\n",
       " 'What is the prognosis in terms of five-year survival for lung cancer patients undergoing Keytruda therapy?',\n",
       " 'What is the likelihood of survival beyond five years for patients with lung cancer who are prescribed Keytruda?',\n",
       " 'What is the expected survival rate at the five-year mark for individuals with lung cancer treated with Keytruda?',\n",
       " 'What was the objective response rate observed in the KEYNOTE-006 study?',\n",
       " 'What was the rate of objective responses documented in the KEYNOTE-006 clinical trial?',\n",
       " 'What was the objective response rate reported in the KEYNOTE-006 research?',\n",
       " 'What percentage of patients showed objective responses in the KEYNOTE-006 trial?',\n",
       " 'What was the objective response rate achieved in the KEYNOTE-006 investigation?',\n",
       " 'What monitoring guidelines are recommended for NSCLC patients receiving Keytruda based on KEYNOTE-006 study results?',\n",
       " 'Are there specific monitoring protocols advised for NSCLC patients treated with Keytruda according to the outcomes of KEYNOTE-006?',\n",
       " 'What monitoring measures should be implemented for NSCLC patients on Keytruda in line with the findings from KEYNOTE-006?',\n",
       " 'How are NSCLC patients prescribed Keytruda monitored based on the results of KEYNOTE-006?',\n",
       " 'What monitoring strategies are suggested for NSCLC patients undergoing Keytruda treatment following the KEYNOTE-006 trial outcomes?',\n",
       " 'What were the outcomes of Keytruda treatment in patients with metastatic NSCLC in the KEYNOTE-051 trial?',\n",
       " 'How did Keytruda affect metastatic NSCLC patients participating in the KEYNOTE-051 trial?',\n",
       " \"What results were observed in the KEYNOTE-051 trial regarding Keytruda's impact on metastatic NSCLC?\",\n",
       " 'What was the response of metastatic NSCLC patients to Keytruda treatment in the KEYNOTE-051 trial?',\n",
       " \"What findings were reported regarding Keytruda's efficacy in metastatic NSCLC based on the KEYNOTE-051 trial?\",\n",
       " 'Were the primary endpoints of the KEYNOTE-10086 trial achieved?',\n",
       " 'Did the KEYNOTE-10086 trial demonstrate success in meeting its primary goals?',\n",
       " 'Were the main objectives of the KEYNOTE-10086 trial fulfilled?',\n",
       " 'Did the KEYNOTE-10086 trial show positive outcomes in terms of primary endpoints?',\n",
       " 'Were the primary endpoints of the KEYNOTE-10086 trial successfully reached?',\n",
       " 'Which adverse reactions were documented in the KEYNOTE-006 study?',\n",
       " 'What side effects were observed during the KEYNOTE-006 clinical trial?',\n",
       " 'What were the reported adverse events in the KEYNOTE-006 trial?',\n",
       " 'Which side effects were specifically noted in the KEYNOTE-006 study?',\n",
       " 'What were the documented side effects in the KEYNOTE-006 research?',\n",
       " 'What is the standard dosage regimen of Keytruda for treating melanoma?',\n",
       " 'How is the dosage of Keytruda typically prescribed for melanoma patients?',\n",
       " 'What is the appropriate dosing schedule for Keytruda in melanoma therapy?',\n",
       " 'What is the usual dosage strength recommended for Keytruda in melanoma treatment?',\n",
       " 'How is the dosage of Keytruda adjusted based on the severity of melanoma in patients?',\n",
       " 'In what ways do the findings of KEYNOTE-006 impact the future research strategies for treating NSCLC?',\n",
       " 'What implications do the results of KEYNOTE-006 have on the future research pathways for NSCLC therapy?',\n",
       " 'How do the outcomes of KEYNOTE-006 shape the future investigative focus for NSCLC treatment?',\n",
       " 'What influence do the results of KEYNOTE-006 have on the future research directions for managing NSCLC?',\n",
       " 'What changes in research priorities for NSCLC treatment are suggested by the results of KEYNOTE-006?',\n",
       " 'What is the typical method of administering Keytruda to patients?',\n",
       " 'In what manner is Keytruda usually given to individuals undergoing treatment?',\n",
       " 'How is Keytruda typically delivered to patients for cancer therapy?',\n",
       " 'What is the standard procedure for administering Keytruda to cancer patients?',\n",
       " 'By what means is Keytruda commonly administered to individuals receiving cancer treatment?',\n",
       " 'Is Keytruda commonly combined with other treatment modalities?',\n",
       " 'What are the potential benefits of using Keytruda in conjunction with other therapies?',\n",
       " 'Are there specific medications that are frequently paired with Keytruda in cancer treatment?',\n",
       " 'How does the effectiveness of Keytruda change when used in combination with other therapies?',\n",
       " 'What considerations should be taken into account when combining Keytruda with other treatment options?',\n",
       " \"What are the recommended protocols for using Keytruda in the treatment of Hodgkin's lymphoma?\",\n",
       " \"Which specific guidelines should be followed when utilizing Keytruda for Hodgkin's lymphoma therapy?\",\n",
       " \"What are the established recommendations for Keytruda administration in Hodgkin's lymphoma patients?\",\n",
       " \"How should Keytruda be appropriately used in the management of Hodgkin's lymphoma based on guidelines?\",\n",
       " \"What are the standard practices for incorporating Keytruda into the treatment regimen for Hodgkin's lymphoma?\",\n",
       " 'What resources are offered to patients using Keytruda through support programs?',\n",
       " 'Are there specific programs designed to assist patients prescribed Keytruda?',\n",
       " 'What support services are accessible to individuals taking Keytruda?',\n",
       " 'Do Keytruda users have access to patient support programs for assistance?',\n",
       " 'Which programs are available to support patients using Keytruda?',\n",
       " 'In what ways is awareness being promoted for Keytruda as a viable treatment choice?',\n",
       " 'What efforts are being made to increase awareness about Keytruda as a treatment option?',\n",
       " 'How is awareness being heightened regarding the use of Keytruda in cancer therapy?',\n",
       " 'What strategies are in place to educate patients about Keytruda as a potential treatment?',\n",
       " 'In what ways are healthcare professionals spreading awareness about Keytruda as a therapeutic option?',\n",
       " 'Are there any patient support groups available for individuals receiving Keytruda therapy?',\n",
       " 'Is there a network or community for patients being treated with Keytruda to connect with?',\n",
       " 'Are there resources or groups specifically designed for Keytruda patients seeking support?',\n",
       " 'Do patients undergoing Keytruda treatment have access to support groups or communities?',\n",
       " 'Are there organized support systems for individuals undergoing Keytruda therapy?',\n",
       " 'In what ways do healthcare professionals inform patients about the advantages and potential drawbacks of Keytruda?',\n",
       " 'What methods are used by healthcare providers to educate patients on the benefits and risks associated with Keytruda?',\n",
       " 'How do medical practitioners communicate the benefits and potential risks of Keytruda to their patients?',\n",
       " 'What strategies do healthcare providers employ to discuss the benefits and risks of Keytruda with patients?',\n",
       " 'In what manner do healthcare professionals convey information about the benefits and risks of Keytruda to patients?',\n",
       " 'In what ways does Keytruda enhance survival outcomes for NSCLC patients in comparison to conventional therapies?',\n",
       " 'What benefits does Keytruda offer in terms of survival rates for NSCLC patients versus standard treatments?',\n",
       " 'How does Keytruda impact the survival rates of NSCLC patients when contrasted with traditional therapies?',\n",
       " 'What is the effect of Keytruda on the survival rates of NSCLC patients relative to conventional treatments?',\n",
       " 'What improvements in survival rates can NSCLC patients expect from Keytruda compared to standard therapies?',\n",
       " 'Is there a potential for Keytruda to impact blood pressure levels?',\n",
       " 'Can Keytruda lead to fluctuations in blood pressure readings?',\n",
       " 'Are changes in blood pressure a known effect of Keytruda treatment?',\n",
       " 'Does Keytruda have the ability to influence blood pressure values?',\n",
       " 'What is the relationship between Keytruda and alterations in blood pressure?',\n",
       " 'Which side effects of Keytruda should NSCLC patients be vigilant about monitoring?',\n",
       " 'What particular side effects of Keytruda are crucial for NSCLC patients to keep track of?',\n",
       " 'Are there any specific adverse effects of Keytruda that NSCLC patients need to watch for?',\n",
       " 'What are the key side effects of Keytruda that NSCLC patients should be monitoring closely?',\n",
       " 'Which side effects of Keytruda are especially important for NSCLC patients to be mindful of?',\n",
       " 'In KEYNOTE-051, what is the comparative effectiveness of Keytruda in treating NSCLC between smokers and non-smokers?',\n",
       " 'What differences in efficacy of Keytruda have been observed in smokers versus non-smokers with NSCLC in the KEYNOTE-051 study?',\n",
       " \"How does Keytruda's efficacy vary between smokers and non-smokers with NSCLC according to data from KEYNOTE-051?\",\n",
       " 'What is the response rate of Keytruda in NSCLC patients who smoke compared to those who do not smoke in the KEYNOTE-051 trial?',\n",
       " 'What are the outcomes of Keytruda treatment in NSCLC patients based on smoking status in the KEYNOTE-051 study?',\n",
       " 'Which genetic markers were analyzed in NSCLC patients as part of the KEYNOTE-006 trial?',\n",
       " 'What specific genetic markers were investigated in NSCLC patients in the context of the KEYNOTE-006 study?',\n",
       " 'What genetic characteristics were examined in NSCLC patients enrolled in the KEYNOTE-006 clinical trial?',\n",
       " 'Which genetic markers were specifically focused on in NSCLC patients during the KEYNOTE-006 research?',\n",
       " 'What genetic profiles were assessed in NSCLC patients participating in the KEYNOTE-006 trial?',\n",
       " 'Which genetic markers are typically screened for prior to initiating Keytruda treatment in patients with NSCLC?',\n",
       " 'What specific genetic markers are evaluated before commencing Keytruda therapy for NSCLC?',\n",
       " 'What genetic indicators are examined before starting Keytruda in NSCLC patients?',\n",
       " 'Prior to starting Keytruda in NSCLC patients, what genetic markers are usually tested?',\n",
       " 'What genetic markers are assessed before initiating Keytruda for NSCLC treatment?',\n",
       " 'Do treatment outcomes with Keytruda vary between smokers and non-smokers diagnosed with NSCLC?',\n",
       " 'Are there differences in Keytruda treatment response based on smoking status in NSCLC patients?',\n",
       " 'How does smoking status impact the effectiveness of Keytruda in treating NSCLC?',\n",
       " 'Is there a correlation between smoking history and treatment response to Keytruda in NSCLC patients?',\n",
       " 'Do smokers and non-smokers with NSCLC show different responses to Keytruda therapy in terms of treatment outcomes?',\n",
       " 'Is Keytruda a viable treatment option for NSCLC patients with brain metastases?',\n",
       " 'Can Keytruda effectively target brain metastases in NSCLC patients?',\n",
       " 'Are NSCLC patients with brain metastases candidates for Keytruda therapy?',\n",
       " 'Is Keytruda considered a suitable treatment for NSCLC patients with brain metastases?',\n",
       " 'What is the efficacy of Keytruda in treating NSCLC patients with brain metastases?',\n",
       " 'What treatment alternatives are available for NSCLC patients who show no response to Keytruda?',\n",
       " 'In cases of Keytruda resistance in NSCLC patients, what other therapeutic options can be considered?',\n",
       " 'What are the next steps for NSCLC patients who fail to respond to Keytruda treatment?',\n",
       " 'What are the alternative medications for NSCLC patients who do not have a positive response to Keytruda?',\n",
       " 'What are the strategies for managing NSCLC patients who do not exhibit a favorable reaction to Keytruda?',\n",
       " 'In what manner does Keytruda interact with other treatments for NSCLC?',\n",
       " 'What is the mechanism of action of Keytruda when used alongside other therapies for NSCLC?',\n",
       " 'How does Keytruda complement other treatment modalities for NSCLC?',\n",
       " 'What role does Keytruda play when combined with other therapies for NSCLC?',\n",
       " 'What synergistic effects are observed when Keytruda is used in conjunction with other treatments for NSCLC?',\n",
       " 'What assistance programs are available for NSCLC patients requiring Keytruda therapy?',\n",
       " 'Which financial aid options exist for NSCLC patients seeking Keytruda treatment?',\n",
       " 'What support resources can NSCLC patients access to help cover the costs of Keytruda?',\n",
       " 'How can NSCLC patients needing Keytruda treatment find financial assistance?',\n",
       " 'What financial support options are specifically tailored for NSCLC patients receiving Keytruda therapy?',\n",
       " 'Is fatigue a common side effect experienced by NSCLC patients treated with Keytruda?',\n",
       " 'What is the likelihood of Keytruda inducing fatigue in patients with NSCLC?',\n",
       " 'Do NSCLC patients frequently report fatigue as a result of Keytruda treatment?',\n",
       " 'How does Keytruda impact fatigue levels in individuals with NSCLC?',\n",
       " 'Are NSCLC patients at risk of developing fatigue while using Keytruda?',\n",
       " 'What new developments are being explored for Keytruda in the treatment of NSCLC?',\n",
       " 'Which research areas are focusing on advancements in Keytruda for NSCLC therapy?',\n",
       " 'What progress is being made in studying Keytruda for NSCLC treatment?',\n",
       " 'How are researchers investigating improvements in Keytruda for NSCLC management?',\n",
       " 'What innovations are being pursued for Keytruda in the context of NSCLC therapy?',\n",
       " 'What impact does Keytruda have on the immune system function of patients with NSCLC?',\n",
       " 'In what way does Keytruda influence the immune system function of NSCLC patients?',\n",
       " 'How does Keytruda specifically affect the immune response in NSCLC patients?',\n",
       " 'What changes occur in the immune system function of NSCLC patients when treated with Keytruda?',\n",
       " 'What is the relationship between Keytruda and immune system function in NSCLC patients?',\n",
       " 'What factors determine the cessation of Keytruda treatment in patients with NSCLC?',\n",
       " 'Which conditions warrant the discontinuation of Keytruda in NSCLC patients?',\n",
       " 'What guidelines exist for stopping Keytruda therapy in NSCLC patients?',\n",
       " 'When is it necessary to halt Keytruda treatment in NSCLC patients?',\n",
       " 'What circumstances lead to the discontinuation of Keytruda in patients with NSCLC?',\n",
       " 'In NSCLC patients with specific genetic alterations, how does Keytruda compare to targeted therapies based on KEYNOTE-006 data?',\n",
       " 'What was the comparative efficacy of Keytruda versus targeted therapies in NSCLC patients with specific genetic alterations according to KEYNOTE-006 results?',\n",
       " 'How does Keytruda stack up against targeted therapies in NSCLC patients with specific genetic alterations as shown in the KEYNOTE-006 study?',\n",
       " 'What were the findings regarding the comparison between Keytruda and targeted therapies in NSCLC patients with specific genetic alterations in the KEYNOTE-006 trial?',\n",
       " 'In the context of NSCLC patients with specific genetic alterations, what were the outcomes of Keytruda compared to targeted therapies in the KEYNOTE-006 research?',\n",
       " 'What indicators suggest a favorable outcome to Keytruda treatment in NSCLC?',\n",
       " 'How can a positive response to Keytruda be recognized in patients with NSCLC?',\n",
       " 'What are the signals that indicate a beneficial reaction to Keytruda in NSCLC cases?',\n",
       " 'Which signs point towards a successful response to Keytruda therapy for NSCLC?',\n",
       " 'What are the markers of an effective response to Keytruda specifically in NSCLC patients?',\n",
       " 'Is Keytruda considered safe for use in NSCLC patients with autoimmune diseases?',\n",
       " 'What is the suitability of Keytruda for NSCLC patients who also have autoimmune diseases?',\n",
       " 'Can Keytruda be administered to NSCLC patients diagnosed with autoimmune conditions?',\n",
       " 'Are there any concerns regarding the use of Keytruda in NSCLC patients with autoimmune diseases?',\n",
       " 'What is the compatibility of Keytruda with NSCLC patients who have autoimmune disorders?',\n",
       " 'How do the survival rates of NSCLC patients on Keytruda compare to those on conventional chemotherapy?',\n",
       " 'What is the difference in survival outcomes between NSCLC patients receiving Keytruda versus traditional chemotherapy?',\n",
       " 'In NSCLC treatment, what are the survival rate differences between Keytruda and standard chemotherapy?',\n",
       " 'What are the comparative survival rates of NSCLC patients treated with Keytruda versus those treated with standard chemo?',\n",
       " 'How do the survival outcomes vary between NSCLC patients treated with Keytruda and those treated with traditional chemotherapy?',\n",
       " 'In KEYNOTE-789, what proportion of NSCLC patients achieved complete remission with Keytruda therapy?',\n",
       " 'What is the rate of complete remission among NSCLC patients treated with Keytruda in the KEYNOTE-789 trial?',\n",
       " 'How many NSCLC patients in KEYNOTE-789 saw complete remission as a result of Keytruda treatment?',\n",
       " 'What percentage of NSCLC patients in the KEYNOTE-789 study experienced full remission with Keytruda therapy?',\n",
       " 'What is the complete remission rate for NSCLC patients receiving Keytruda in the context of the KEYNOTE-789 trial?']"
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ds = df[[\"augmented_questions\"]].rename(columns = {\"augmented_questions\":\"question\"})\n",
    "\n",
    "ds_dict = ds.to_dict()\n",
    "ds_dict[\"question\"] = [v for k, v in ds_dict[\"question\"].items()] \n",
    "ds_dict[\"question\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Dataset({\n",
       "    features: ['question'],\n",
       "    num_rows: 220\n",
       "})"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from datasets import Dataset\n",
    "\n",
    "ds_dict = ds.to_dict()\n",
    "ds_dict[\"question\"] = [v for k, v in ds_dict[\"question\"].items()] \n",
    "\n",
    "dataset = Dataset.from_dict(ds_dict)\n",
    "dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "from ragas.integrations.llama_index import evaluate\n",
    "\n",
    "result = evaluate(\n",
    "    query_engine=query_engine,\n",
    "    metrics=metrics,\n",
    "    dataset=dataset,\n",
    "    llm=evaluator_llm,\n",
    "    embeddings=OpenAIEmbedding(),\n",
    ")\n",
    "\n",
    "df_result = result.to_pandas()\n",
    "df_result.to_parquet(\"../data/processed_data/df_result_ragas_without_reranking.parquet\")\n",
    "\n",
    "df_result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>faithfulness</th>\n",
       "      <th>answer_relevancy</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>218.000000</td>\n",
       "      <td>220.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>0.831684</td>\n",
       "      <td>0.859019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>0.297590</td>\n",
       "      <td>0.301806</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>0.666667</td>\n",
       "      <td>0.949170</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.964384</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.974852</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>1.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       faithfulness  answer_relevancy\n",
       "count    218.000000        220.000000\n",
       "mean       0.831684          0.859019\n",
       "std        0.297590          0.301806\n",
       "min        0.000000          0.000000\n",
       "25%        0.666667          0.949170\n",
       "50%        1.000000          0.964384\n",
       "75%        1.000000          0.974852\n",
       "max        1.000000          1.000000"
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# without reranking\n",
    "df_result.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>faithfulness</th>\n",
       "      <th>answer_relevancy</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>219.000000</td>\n",
       "      <td>220.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>0.793747</td>\n",
       "      <td>0.890620</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>0.314552</td>\n",
       "      <td>0.259305</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.949299</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.966063</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.978517</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>1.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       faithfulness  answer_relevancy\n",
       "count    219.000000        220.000000\n",
       "mean       0.793747          0.890620\n",
       "std        0.314552          0.259305\n",
       "min        0.000000          0.000000\n",
       "25%        0.500000          0.949299\n",
       "50%        1.000000          0.966063\n",
       "75%        1.000000          0.978517\n",
       "max        1.000000          1.000000"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# with reranking\n",
    "df_result.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
